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ABSTRACT
ENDOCRINE DISRUPTERS AND ADVERSE HEALTH OUTCOMES AMONG
POSTMENOPAUSAL WOMEN
MAY 2022
GABRIELA VIEYRA, B.S., UNIVERSITY OF NEVADA RENO
M.P.H., UNIVERSITY OF NEVADA RENO
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by Associate Professor Katherine W. Reeves

Globally, chronic diseases that require ongoing medical attention, and limit daily
living activities, are the leading cause of disability and mortality. The older population in
the U.S. is rapidly growing, and the risk of chronic diseases is higher in this population,
specifically older women. In 2018, 51.3% of women compared to 41.8% of men had two
or more chronic conditions. Thus, the Women’s Health Initiative (WHI) study, Chapter 1,
focused on preventing leading causes of death, disability, and frailty in older women.
Phthalates are synthetic industrial compounds, Chapter 2, commonly added to daily used
consumer goods, nutritional and dietary supplements, and plastic food packaging. Current
literature suggests that phthalate exposure may be associated with an increased risk of
chronic health outcomes, including excess adiposity via disruption of metabolic
processes/adipocyte function and cardiovascular disease (CVD) via disruption of normal
cardiac function. Thus, this dissertation aimed to evaluate these associations between
dietary patterns, excess adiposity, CVD, and phthalate exposure in the prospective WHI
study (n=161,808).
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In chapter 3, we evaluated how alignment to specific dietary patterns, dietary
approach to stop hypertension (DASH), the alternative Mediterranean diet (aMed), and
the dietary inflammation index (DII) are associated with urinary phthalate biomarker
concentrations. Results of this study suggest that higher alignment with diets promoting
consumption of whole fruits and vegetables, including the DASH and aMed, are
associated with lower concentrations of phthalate biomarkers.
In chapter 4, we evaluate the association between phthalate exposure and dualenergy x-ray absorptiometry (DXA) derived visceral adipose tissue (VAT) and
subcutaneous adipose tissue (SAT). Our findings indicate that higher concentrations of
phthalates are more strongly associated with increased VAT.
In chapter 5, we evaluate the association between phthalate exposure and
adjudicated incident cases of CVD. Our findings suggest that increased concentrations of
phthalates may be associated with increased CVD risk among nonusers of hormone
therapy.
In conclusion, our findings suggest that phthalates are associated with increased
VAT and may be associated with increased CVD risk. However, consumption of dietary
patterns like the DASH and Mediterranean diets may be a non-invasive means of
mitigating phthalate exposure and subsequent chronic disease risk.
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CHAPTER 1
STUDY POPULATION
1.1

Introduction
Chronic diseases-physical or mental health conditions that last one or more years-

require ongoing medical attention, limit daily living activities, are the leading cause of
disability and mortality worldwide. (1),(2) Globally, the three leading causes of death are
chronic diseases (i.e., cardiovascular disease [CVD], ischemic heart disease [IHD], and
chronic obstructive pulmonary disease [COPD]). (3,4) In 2019, 17.9 million people died,
representing 31% of global deaths. (3) In the United States (U.S.), chronic diseases are
the leading cause of disability and death, causing 7 out of 10 deaths each year. According
to the healthy people 2020 report, 107 million Americans had at least 1 of 6 reported
chronic diseases (e.g., CVD, arthritis, diabetes, asthma, cancer, and COPD) and 4 of 10
had two or more. (5) Older adults experience a higher risk of chronic diseases. (6)
The older population in the U.S. is rapidly growing, and the risk of chronic diseases
is higher in this population. In 2018, 54.3% of adults 45 years and older had at least one
chronic condition, and 63.7% of those 65 and older had two or more. (7,8) Moreover, the
risk is higher for women than men, 80.1% vs. 75.3%, for one chronic condition and
51.3% vs. 41.8%, for two or more chronic conditions. (7) Chronic conditions, including
CVD, cancer, and osteoporosis, are the most common chronic diseases among older
women. (9,10) CVD, typically thought of as a man’s disease, is the leading cause of
death for women accounting for 1 in 5 female deaths; nearly 48 million women are living
with or at risk of heart diseases. (9,11) Note, in 2019, 16.5% (52 million) of the U.S.

1

population was aged 65 or older and projected to increase to 23% (95 million) by 2060.
(12)
Historically, studies evaluating risks of death and chronic health outcomes used
male models, and findings were generalized to women. (10) For example, protocols for
diagnosing and treating heart disease were based on findings from middle-aged white
males. (10) However, the validity and practice of utilizing the male model were
questioned with respect to female health issues highlighting gender differences in
biological and social determinants. (10,13) Despite the progress and improvement in
diagnosis, today, only about 56% of women recognize that the leading cause of death
among women is heart disease, 50% are likely to receive a misdiagnosis, and the burden
of chronic diseases continues to be higher among older women. (7,10,11) Thus, studies
like the Women’s Health Initiative (WHI) strive to improve health among older and
postmenopausal women through research on risk factors, prevention, and early detection
of chronic health conditions. (14)
1.2

Women’s Health Initiative Study
The WHI study is a long-term national health study that began in the early 1990s

and concluded in 2005. The WHI, sponsored by the National Heart, Lung, and Blood
Institute (NHLBI), focuses on prevention strategies of chronic diseases, including
cardiovascular disease, breast and colorectal cancers, and osteoporosis, the leading causes
of frailty, disability, and death among postmenopausal women of all races and
socioeconomic backgrounds. (15),(16) Extension studies have continued since 2005,
which include annual collections of health updates and outcomes inactive participants.
(15) The original study consisted of three parts: clinical trials (CT), an observational

2

study (OS), and a community prevention study. (15),(16) The clinical and observational
studies were conducted at 40 clinical centers nationwide. Between October 1, 1993, to
December 21, 1998, the WHI recruited 161,808 women aged 50 to 79 years from the 40
clinical centers. Participants were included if they did not have a medical condition
predictive of a survival time of fewer than three years, competing risks (e.g., invasive
cancer in the past ten years and having chronic illnesses), and adherence or retention
reasons (i.e., unwillingness or inability to complete baseline study requirements). (16) A
total of 68,132 women were enrolled into the CT, and 93,676 in the OS.
1.2.1

Study Population
Three clinical sites (N=11,020) included a bone density sub-study for all

participants and were the only sites that collected urine samples. (17) WHI participants
enrolled from these sites (Birmingham, AL; Pittsburgh, PA; Tucson/Phoenix, AZ)
provided first-morning void urine samples at baseline, annual visit (AV) 1, and AV3.
Eligible participants had no prior history of cancer other than non-melanoma skin cancer
and had at least two urine samples available.
The present analysis includes participants selected from a nested case-control
study of phthalate biomarkers and breast cancer (N=1,257, Figure 1.1). A total of 419
invasive breast cancer cases and 838 controls, matched on enrollment date, length of
follow-up, age at enrollment, and study arm, were selected; both cases and controls are
included in all subsequent analyses. Participants provided written informed consent upon
enrollment into WHI. Study protocols were reviewed and approved by institutional
review boards (IRBs) at each WHI clinical center.

3

Figure 1.1 Study population for current analyses.
1.3

Dissertation Aims

Diet and Phthalates
Specific Aim #1: To determine how alignment to specific dietary patterns, DASH and
aMed, is associated with urinary phthalate biomarker concentrations.
Specific Aim #2: Evaluate the association between diet-induced inflammation, as
presented by the dietary inflammation index (DII), and urinary phthalate biomarker
concentrations.
Phthalates and Adiposity
Specific Aim #1: To evaluate the cross-sectional associations between urinary phthalate
biomarker concentrations and adiposity, specifically DXA-derived VAT and SAT.
Specific Aim #2: To prospectively evaluate the association between urinary phthalate
biomarker concentrations and adiposity, specifically VAT & SAT.
Phthalates and CVD
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Specific Aim #1: To prospectively evaluate the association between urinary phthalate
biomarker concentrations and clinical incident cardiovascular disease among an older
population of postmenopausal women.
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CHAPTER 2
PHTHALATE BIOMARKERS
2.1

Introduction
Phthalate biomarkers constitute a diverse family of synthetic organic man-made

industrial compounds used to increase the flexibility and durability of plastic products,
specifically polyvinyl chloride (PVC) products. (18),(19) They are commonly used in
various consumer products, including building materials, automotive parts, household
furnishings, medical devices, cosmetics, perfumes, toys, dentures, adhesives, paints,
floorings, lubricants, hair sprays, shampoos, nail polishes, and cleaning materials,
becoming an unavoidable part of modern life. (20–23) An estimated 213.2 million kg of
phthalates are produced and imported into the U.S. annually, making it the second most
commonly used plasticizer in the world. (18),(19),(24) Notably, phthalates are also used
in nutritional supplements, dietary supplements, and food packaging. (20)-(23)
Phthalate biomarkers at low acute exposures have low toxicity levels and
reactions, including weak skin and eye irritations and generally negative or weak
sensitizers. (25) Notably, phthalates do not present with a typical dose-response curve;
increased concentrations do not necessarily correspond with an increase in their effect
(i.e., non-monotonic curves). (26) However, chronic exposure in animal models have
shown phthalate biomarkers to be toxic to the liver, increasing liver weight, peroxisome
proliferation, and histopathological effects in kidneys. (20,25) Other toxic effects
associated with chronic exposure include malformations from in utero exposure to di (2Ethylhexyl) phthalate (DEHP) and reproductive, developmental, and carcinogenic
effects. (20,22,23,25,27)
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Human studies have also observed associations between phthalate exposure and
health outcomes. Phthalate exposure has specifically been associated with infertility
outcomes; increased exposure to DEHP was inversely associated with semen parameters
(e.g., semen count, quality, and motility) among males and decreased oocyte quality,
clinical pregnancies, and live births among females. (22–25,28,29) Moreover, congenital
malformations, including hypospadias, cryptorchidism, and shortening of anogenital
distance (AGD), have been associated with in utero exposure to DBP, DEHP, and BBP
exposure. (22,23,28) However, these studies had several limitations, including the
studies’ population and rarity of the outcomes; infertility studies included populations
that were sub-fertile and were undergoing infertility treatment. Further, hypospadias,
cryptorchidism, and shortening of AGD are rare congenital malformations in the general
population, which yields small case numbers making prospective studies difficult.
Although associations between phthalates exposure and fertility outcomes are more
consistent, studies on associations with chronic health outcomes have been less consistent
and the mechanistic role of phthalates is still being understood.
The toxicity classification of phthalate biomarkers is currently under review by
the Environmental Protection Agency (EPA). (24,30,31) Three phthalates have been
banned from use in baby toys only (i.e., DEHP, DBP, and BBzP). (24) DIDP and DINP are
being assessed for risk by the EPA with no official results yet available. Further, the EPA
is in the planning phase to assess other commonly used phthalate biomarkers for risk on
health outcomes and toxicity (e.g., DIDP, DINP, DIBP, DnOP, and DnPP). (31)
Phthalates are present in most daily used consumer products, and although they are
known to be quickly metabolized and excreted, the problem lies in their almost
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continuous exposure, making them semi-persistent chemicals. This chapter provides a
general overview of the biology, specifications, and toxicokinetics of commonly used
phthalate biomarkers.
2.2

Biology & Toxicokinetic
Phthalates are esters of phthalic acid (1,2-di benzene dicarboxylic acid), a result of

the phthalic acid reaction with specific alcohols, forming esters with the side chain of
interest. (18),(19) In their pure form, phthalates are typically clear liquids, and some have a
faint yellowish color and sweet odor. (32) Structurally, phthalates have one benzene ring
and two paired esters (Figure 2.1); the hydrocarbon chains, which form from the esters
with various structures, give each phthalate its different physical properties (i.e., heavy
molecular weight [HMW] phthalates vs. low molecular weight [LMW] phthalates).

Figure 2.1 General chemical structure of phthalates
High molecular weight (HMW) phthalates
HMW phthalates typically have ester side-chain lengths of five or more carbons.
(27),(33) HMW phthalates (e.g., DEHP and BBzP) are primarily used as plasticizers in
the manufacturing of flexible vinyl for flooring and wall covering, medical devices, and
food and food containers/packaging. (18,19,23) Some phthalate biomarkers are highly
hydrophobic, logK values ranging from 7.5 to 8.8 (e.g., DEHP, logK 8.8), making them
more lipophilic and more likely to persist in fat reserves. (25,32) Notably, the most
8

detectable HMW phthalate metabolites are oxidized metabolites, a result of the second
step biotransformation needed for excretion; therefore, oxidative metabolites are the
preferred biomarker for DEHP (25,34)
Low molecular weight (LMW) phthalates
Low molecular weight phthalate biomarkers are defined as those with straightchain backbones with one to four carbon atoms in length. (25)-(27) LMW phthalates
(e.g., DEP and DBP) are used in personal care products, solvents, and plasticizers for
cellulose acetate, paints, pharmaceutical products, and diet and nutritional supplements.
(18,19,23) LMW phthalates have low logK values, 1.5-2.5, making them less
hydrophobic and more easily excreted in urine. (25) Monoesters are the most abundant
metabolites of LMW phthalate biomarkers, as they undergo one-step biotransformation
before being excreted. (25,34)
2.2.1

ADMEs

Absorption
Absorption is the transfer of a chemical from the site of exposure (e.g., skin,
mucosa) across the biological barrier into the systemic circulation. (35) In vitro data
demonstrate that phthalates, including DEHP in food, are well absorbed from the
intestine over a wide concentration range. (19,21) MEHP is also observed to be well
absorbed from the intestine, indicating that HMW phthalates are well absorbed following
oral ingestion.
Distribution
Distribution is the transfer of a chemical from one location to another within the
body. (21),(36, p.3) Fat, gastrointestinal (GI) tract, liver, and kidneys are the initial
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repositories for phthalate biomarkers. (21) High-dose exposure studies in animal models
have shown significant fractions of HMW phthalates to accumulate in the liver with
continued cumulative exposure. (21)
Metabolism
Metabolism describes the chemical reactions that change xenobiotics into
compounds that are easier to eliminate. (21,37) In mammals, phthalate biomarkers follow
a two-phase metabolism process (i.e., hydrolysis and conjugation). (21) HMW phthalates
undergo several biotransformation steps, including further hydroxylation and oxidation to
achieve sufficient polarity to be excreted in urine (Figure 3). (21,33) LMW phthalates
only undergo one biotransformation step. (21,33)

Figure 2.2. Metabolic pathways of phthalates
Excretion
Excretion is the process of removing a chemical and its metabolites from the
body. (21,38) Urinary excretion is the primary mode of elimination of phthalate
biomarkers in humans and other mammalian species. (21,33) Phthalate metabolites can
also be excreted in fecal matter. However, this is more commonly observed with HMW
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phthalate metabolites; less than 9% of a given phthalate metabolite is eliminated through
feces. (21,33)
2.2.2

Modes of contamination
Phthalate biomarkers have been measured in various environmental matrices, like

sludge, dust, soil, and water. (19) However, food contamination is typically regarded as a
primary source of phthalate biomarker exposure to humans. (27) Phthalates are generally
non-covalently bonded to the products they are added to, which influences their leaching,
environmental fate, and partitioning characteristics upon product contamination. (23) The
lack of covalent bonds between the plastic matrix and phthalate coupled with lipophilic
characteristics favor the easy release into the different environmental compartments and
subsequent human exposure and uptake. (21,23,33) Ingestion levels of phthalate are
estimated to be 1.03 (µg/kg bw/d). (19,33)
2.3

Quantification of Urinary Phthalate Biomarkers
WHI followed a standard collection, processing, and storage protocol at the three

clinical centers that collected urinary phthalate biomarker samples. First-morning void
urine samples were collected at home, a minimum sample volume of 0.5mL, and
processed within 30 minutes after participants arrived at the clinic. Urine samples were
centrifuged for 5 min at 1330 x g; 1.8mL aliquots were frozen and shipped to McKesson
Bio-services packed in dry ice via overnight FedEx, then stored at -70⁰C. (17,39)
Phthalate metabolites were measured and used as biomarkers to ensure the measured
concentrations relate to endogenous exposure versus contamination.
Laboratory Methods
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Thirteen phthalate metabolites were measured in baseline, AV1 and AV3, urine
samples at the Centers for Disease Control and Prevention (CDC) (Table 1). Urine
samples were processed using enzymatic de-conjugation of glucuronidated analytes.
Concentrations of phthalate biomarkers were quantified after enzymatic hydrolysis of the
conjugated metabolites followed by on-line solid-phase extraction coupled to highperformance liquid chromatography-electrospray ionization-isotope dilution tandem mass
spectrometry. (17),(40) Complete details of the analytical methods are published
elsewhere. (40) Limits of detection (LOD) were in the low ng/mL range (0.2-0.9). Study
samples were randomly distributed through the analytical batches, with cases and
matched controls analyzed together. A blinded 10% quality control sample was included
and used to estimate CVs: MBP 5.4%, MBzP 6.1%, MCNP 4.7%, MCOP 6.3%, MCPP
5.8%, MECPP 4.3%, MEHHP 5.4%, MEHP 19.5%, MEOHP 6.0%, MEP 3.1%, MHBP
9.0%, MHiBP 21.9%, MiBP 10.3%. (17,39) All laboratory staff was masked to the
identity, disease status, and demographic, and risk factor characteristics of the samples.
Creatinine was measured using a Roche Modular PChemistry Analyzer (Indianapolis, IN)
and an enzymatic assay. The limit of detection (LOD) for creatinine was 10 mg/dL, and
CV was 2.5%. Three phthalate biomarkers were calculated as molar sums of their
metabolites (di-n-butyl phthalate (ΣDBP), di-isobutyl phthalate (ΣDiBP), and di(2Ethylhexyl) phthalate (ΣDEHP)): ΣDBP from MBP and MHBP; ΣDiBP from MiBP and
MHiBP; ΣDEHP from MEHP, MEHHP, MEOHP, and MECPP. (17,39)
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Table 2.1. Measured phthalate biomarkers and common metabolites. (41)-(42)
Parent Compound
Benzylbutyl Phthalate
Di-isodecyl phthalate
Di-isononyl phthalate
Di-n-butyl phthalate
Di-ethyl phthalate
*ΣDi(2-ethylhexyl)
phthalate

Abbreviation
BzBP
DDP
DNP
DBP
DEP
DEHP

Major metabolites
*Monobenzyl Phthalate
*Monocarboxy-isononly phthalates
*Monocarboxyoctyl phthalate
*Mono (3-carboxypropyl) phthalate
*Mono-ethyl phthalate
Mono(2-ethylhexyl) phthalate
Mono(2-ethyl-5-carboxypentyl) phthalate
Mono(2-ethyl-5-hydroxyhexyl) phthalate
Mono(2-ethyl-5-oxohexyl) phthalate
*ΣDi-n-butyl phthalate
DBP
Mono-n-butyl phthalate
Mono-3-hydroxybutyl phthalate
*ΣDi-isobutyl phthalate DiBP
Mono-isobutyl phthalate
Mono-2-methyl-2-hydroxypropyl phthalate
*Eight phthalate biomarkers used for all analyses
Σ
Three phthalates calculated from the molar sums of the parent compound metabolites:
ΣDEHP from sum of MEHHP, MEHP, MECPP, and MEOHP
ΣDBP from sum of MBP and MHBP
ΣDiBP from sum of MiBP and MHiBP
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Abbreviations
MBzP
MCNP
MCOP
MCPP
MEP
MEHP
MECPP
MEHHP
MEOHP
MBP
MHBP
MiBP
MHiBP

CHAPTER 3
DIETARY PATTERNS AND URINARY PHTHALATE EXPOSURE AMONG
POSTMENOPAUSAL WOMEN
3.1

Introduction
Phthalates are increasingly linked to a higher risk of numerous chronic health

outcomes, including cancer, obesity, and diabetes. (19,23,27,43–45) Phthalate biomarkers
are typically characterized by their molecular weight (i.e., high molecular weight [HMW]
and low molecular weight [LMW] phthalates). HMW phthalates, like di(2-Ethylhexyl)
phthalate (DEHP) and butyl benzyl phthalate (BBzP), have ester side-chains of five or
more carbons, are more likely to bioaccumulate in fat, and are primarily used as
plasticizers in the manufacturing of flexible vinyl, medical devices, and food containers
and packaging. (19,23),(27),(18,25,32,33) LMW phthalates, like Diethyl phthalate (DEP)
and di-n-butyl phthalate (DBP), have straight-chain backbones, with one to four carbon
atoms in length, are more easily excreted in the urine, and are used in personal care
products, solvents, and plasticizers for cellulose acetate, paints, pharmaceutical products,
and diet and nutritional supplements. (19,23),(27),(18,25,32)
These synthetic chemicals are well-established as endocrine disruptors, and due to
their wide use in consumer products, human exposure is ubiquitous. (46,47) In adults,
dietary intake is a primary source of phthalate exposure, as phthalates are a common
component of food packaging materials. (46,47) Food contamination is primarily from
food packaging; the lack of covalent bonding between chemical and parent materials
leads to significant leaching and volatilization, resulting in contamination. (18,47,48)
Moreover, the lipophilic characteristics of phthalate biomarkers make the chemicals more
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likely to “stick” to foods high in fat, and these foods expose consumers to higher
concentration levels. (19,24,46,47) Phthalate biomarkers do not present with a typical
dose-response curve; increased concentrations do not always correspond with an increase
in effect (i.e., non-monotonic curves). (26)
Phthalate biomarkers at low acute exposure levels may lead to weak skin and eye
irritation. (25) In animal studies, chronic phthalate biomarker exposure has been shown to
be toxic to the liver, have histopathological effects, and activate peroxisome proliferators.
(20,25) Moreover, in utero exposure to DEHP has been associated with congenital
malformations and reproductive, developmental, and carcinogenic effects.
(20,22,23,25,27) Prior human studies have found positive associations between DEHP
and lower levels of estradiol and MCOP and MCNP with decreased bone mineral density
among postmenopausal women. (49,50) Despite the growing evidence, the toxicity
classification of phthalate biomarkers is still under review by the Environmental
Protection Agency (EPA). (24,30,31) Currently, three phthalate biomarkers have been
banned from use in baby toys only (i.e., DEHP DBP and BBzP). (24)
Two recent studies measuring the concentration of phthalate biomarkers in
commonly consumed foods and beverages found higher concentrations of DBP, DEHP,
and di-isobutyl phthalate (DiBP) in high-fat foods and sugary beverages (e.g., meat
products, bread, margarine, canned dinners, deli meats, cheese, sweetened teas, and
sodas) compared to whole fruits and vegetables. (51),(52)
Prior human studies have identified individual food groups (e.g., meat and meat
products, bread, milk and milk products, cheese, and fish and fish products) that are
associated with higher urinary phthalate biomarker concentrations. (53–56) Additionally,
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consumption of fast food, food not prepared at home, and processed foods, were
associated with higher urinary concentrations of DEHP and diisononyl phthalate (DiNP)
metabolites in individuals of all ages.(54),(57) Consumption of a western diet, as
compared to a vegetarian diet, was also associated with higher urinary DEHP biomarker
concentrations. (58) Buckley et al. (59) and Martinez Steele et al. (60) observed that
ultra-processed foods (e.g., sandwiches, hamburgers, french-fries, other potato products,
ice cream, and sodas) were associated with higher urinary concentrations of DiNP, mono
(3-carboxypropyl) phthalate (MCPP), monocarboxy-isononyl phthalate (MCNP), and
mono-carboxy octyl phthalate (MCOP) among individuals six years and older.
While exploring exposure from specific food groups is of interest, dietary patterns
may be more predictive of overall health status and future chronic disease risk than single
food groups and nutrients. (19-20) Dietary patterns consider the quantity, variety, and
combination of different foods, drinks, and nutrients consumed. (63) Additionally,
challenges of evaluating individual foods or food groups include high correlations
between individual nutrients, associations with an individual food group or nutrient that
may be too small to detect, and statistically significant associations that may result simply
by chance or from overuse of analytical tests. (61)-(63)
Several dietary patterns are associated with future chronic disease risk. The
Dietary Approach to Stop Hypertension (DASH) diet is designed to treat and prevent
hypertension without medication. (64) The DASH diet focuses on reduced sodium intake
and increased consumption of foods rich in potassium, calcium, and magnesium (e.g.,
vegetables, fruits, and low-fat dairy foods, whole grains, fish, poultry, and nuts). (64)
Higher adherence to the DASH diet has been associated with a lower risk of chronic
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kidney disease (CKD), heart failure, and atherosclerosis. (65–68) Notably, higher
adherence has also been associated with a lower risk of coronary heart disease (CHD) and
stroke among middle-aged and older women. (69) Similarly, the alternate Mediterranean
diet (aMed) emphasizes consuming fruits, vegetables, whole grains, nuts, and legumes.
(70) Additional recommendations include olive oil as the primary form of fat, low to
moderate consumption of cheese, yogurt, fish, poultry, a week, and rare consumption of
red meat. (70) Higher adherence to the aMed diet has similarly been associated with
decreased risk of type 2 diabetes, hypertension, asthma, stroke, and all-cause
cardiovascular disease (CVD) mortality. (71–74) The dietary inflammation index (DII) is
a quantitative means of assessing the inflammatory potential of diets, based on work
identifying dietary exposure associated with blood concentrations of inflammatory
cytokines. (75–80) Higher DII scores have been associated with CKD incidence and
CKD progression, higher cholesterol, and increased risk of CVD and CVD-related
mortality. (81–84) Moreover, dietary intake with higher DII scores has been associated
with glucose-insulin dysregulation, chronic systemic inflammation, endothelial
dysfunction, and dyslipidemia. (78) Further, DII has been identified as a key tool in
characterizing the inflammatory potential of diets and predicting chronic disease
incidence and mortality. (83,84)
Prior studies have not explored the associations between these dietary patterns
and urinary phthalate concentrations. Therefore, we evaluated the associations between
three specific dietary patterns (i.e., DASH, aMed, and DII) and urinary phthalate
biomarker concentrations among a subset of postmenopausal women enrolled in the
Women’s Health Initiative (WHI).
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3.2
3.2.1

Materials and Methods
Study Population
As previously described, the WHI recruited 161,808 postmenopausal women from

40 clinical centers nationwide between October 1, 1993, and December 21, 1998. (16)
All participants were between the ages of 50 to 79 years at enrollment and participated in
one or more of four clinical trials (CT; N=68,132) or an observational study (OS;
N=93,676). (16) Participants of a bone density substudy at three WHI sites (Birmingham,
AL; Pittsburgh, PA; Tucson/Phoenix, AZ) provided first-morning void urine samples at
baseline, annual visit (AV) 1, and AV3 (N=11,020) and were eligible for inclusion in a
previously conducted prospective nested case-control study of phthalate biomarkers and
breast cancer (N=1,257). (17) A total of 419 invasive breast cancer cases and 838
controls, 1:2 matched on enrollment date, length of follow-up, age at enrollment, and
study arm, were selected. (17) Only invasive breast cancer cases diagnosed after AV3
were included, to ensure that urinary phthalate biomarkers were measured before
diagnosis. Participants eligible for the present analysis met the following criteria: 1) at
least two urine samples between baseline and AV3 and 2) dietary exposure data at
baseline and AV3 (N=1,240).
Written informed consent was obtained from all participants upon their enrollment
into WHI, and approval was received from institutional review boards (IRB) at each WHI
clinical center. The University of Massachusetts Amherst IRB additionally approved the
present research. The involvement of the Centers for Disease Control and Prevention
(CDC) laboratory in the analysis of samples did not constitute an engagement in human
subjects’ research.
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3.2.2

Dietary Pattern Measurement
Dietary intake was assessed by self-administered food frequency questionnaires

(FFQs) reflective of the participant’s average diet intake over the previous three months.
(85) We used these data from baseline and AV3 to calculate scores for adherence to the
DASH and aMed diets and to calculate scores for the DII. Complete calculation details
for these diet scores are presented elsewhere. (75,86,87)
Briefly, the DASH diet contains eight dietary components, measuring total cups
or ounce equivalents of each listed food group: fruits, vegetables, nuts/legumes, whole
grains, low-fat dairy, sodium, red/processed meat, and sweetened beverages. (87,88) The
DASH diet components were integer ranked (1 to 5), with cut-points based on
corresponding quintiles, and then summed. (87,88) DASH scores ranged from 8 to 40,
with higher scores indicating closer conformance to the modern interpretation of the diet.
The aMed diet has nine components, similarly measuring total cups or ounce
equivalents of each listed food group: vegetables, fruits, nuts, whole grains, legumes,
fish, monounsaturated and saturated fat, processed meats, and alcohol. (86,88) The aMed
diet components were scored dichotomously, with cut-points based on corresponding
medians, and then summed. (86),(89) aMed scores ranged from 0 to 9, with a higher score
indicating closer conformance to a Mediterranean diet pattern.
The dietary inflammation index (DII) was developed to assess the quality of diet
with respect to its inflammation potential and the role of diet in health outcomes. (75,76)
It is based on FFQ data and was validated using high sensitive CRP (hsCRP)
measurements in plasma in a longitudinal cohort of 494 individuals followed with
intensive dietary monitoring using 24-h recall interviews and 7-day diet recalls for a year,
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presented elsewhere. (75) DII scores range from maximally anti-inflammatory to
maximally pro-inflammatory (i.e., -7.25 to 6.03). (90)
Total dietary scores were z-score standardized (i.e., total dietary score was
subtracted from the mean dietary score and divided by respective standard deviation).
3.2.3

Quantification of Urinary Phthalate Metabolites
WHI followed a standard urine collection, processing, and storage protocol. First

morning void urine samples were collected at home and processed <30 minutes upon
clinic arrival. Urine samples were centrifuged for 5 minutes at 1330 x g; 1.8mL aliquots
were frozen and shipped to McKesson Bio-services packed in dry ice via overnight
FedEx then stored at -70°C.
Phthalate metabolites are used as biomarkers to ensure that measured
concentrations relate to endogenous exposures. The Personal Care Products Laboratory at
the Centers for Disease Control and Prevention quantified thirteen phthalate metabolites
in urine samples provided at baseline, AV1, and AV3 (mono-n-butyl phthalate [MBP],
monobenzyl phthalate [MBzP], MCNP, mono-carboxyoctyl phthalate [MCOP], MCPP,
mono(2-ethyl-5-carboxypentyl) phthalate [MECPP], mono-(2-ethyl-5-hydroxyhexyl)
phthalate [MEHHP], mono-(2-ethylhexyl) phthalate [MEHP], mono(2-ethyl-5-oxohexyl)
phthalate [MEOHP], monoethyl phthalate [MEP], mono-hydroxybutyl phthalate
[MHBP], mono-hydroxyisobutyl phthalate [MHiBP], and monoisobutyl phthalate
[MiBP]). The glucuronidated phthalate metabolites undergo enzymatic deconjugation
followed by on-line solid phase extraction and high-performance liquid chromatographyelectrospray ionization-tandem mass spectrometry. Samples were randomly distributed
through the batches, with all replicates from cases and matched controls analyzed

20

together. A blinded 10% quality control sample was included and used to estimate CVs:
MBP 5.4%, MBzP 6.1%, MCNP 4.7%, MCOP 6.3%, MCPP 5.8%, MECPP 4.3%,
MEHHP 5.4%, MEHP 19.5%, MEOHP 6.0%, MEP 3.1%, MHBP 9.0%, MHiBP 21.9%,
MiBP 10.3%. Laboratory staff were masked to the identity, disease status, and
demographic and risk factor characteristics of the samples. Creatinine was measured
using a Roche Modular P Chemistry Analyzer (Indianapolis, IN) and an enzymatic assay.
The limit of detection (LOD) for creatinine was 1 mg/dL and the CV was 2.5%. (91)-(92)
3.2.4

Covariate Data
Participants provided extensive data via self-reported questionnaires and at annual

clinic visits. We considered the following potential covariates assessed at baseline, with
updates at subsequent clinic visits for time-varying covariates: creatinine (continuous),
age (continuous), region (Northeast, South, West), education (less than high school, high
school/some college, college graduate, graduate degree), income (<$35,000, ≥$35,000),
current alcohol intake (non-drinker, past drinker, <1 drink per month, <1 drink per week,
1-<7 drinks per week, 7+ drinks per week), smoking status (never, past, current), body
mass index (BMI) (continuous, kg/m2), measured during annual clinic visits, total
physical activity METs/week (quartiles), dietary animal protein (continuous), dietary
vegetable protein (continuous), and dietary energy (continuous, kcal). The dietary animal
and vegetable protein variables are independent variables and were not utilized in
calculating the dietary pattern scores.
3.2.5

Statistical Analysis

Phthalate biomarker concentrations were natural log-transformed to improve
normality. Phthalate biomarkers, measured between baseline and AV3, were analyzed as
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continuous variables. Sum of metabolites of di-n-butyl phthalate (ΣDBP), di-isobutyl
phthalate (ΣDiBP), and di(2-Ethylhexyl) phthalate (ΣDEHP) were calculated as the molar
sum of ΣDBP from MBP and MHBP; ΣDiBP from MiBP and MHiBP; ΣDEHP from
MEHP, MEHHP, MEOHP, and MECPP. Dietary exposure data, DASH and aMed diet,
and DII scores, measured at baseline and AV3, were analyzed continuously.
Generalized Estimating Equation (GEE) models were fit using the identity link and
Gaussian (normal) distribution to estimate cross-sectional associations between each
dietary pattern and the phthalate biomarkers. This approach has the advantage of
accommodating repeated measures, including updated covariate information at each time
point. Initially, we fit a single GEE model for each phthalate biomarker, creatinine, age,
and a single covariate.
In the multivariable GEE model development, all variables from the single predictor
models, significant at the p<0.25 level, were included in our initial multiple predictors
model. In subsequent model selection, age and creatinine were retained in all models,
regardless of statistical significance. In selecting our final multivariable model, we
utilized multiple criteria, including the significance of the partial F-tests (p<0.05) and
changes in the magnitudes in the estimated regression coefficients (≥;10%), this yielded
the following covariates for inclusion in our final multivariable models: age, region,
education level, alcohol consumption, dietary energy intake, and dietary animal protein.
Note, given the high collinearity of race and region, we only adjusted for region in our
analyses. Moreover, we adjusted models for BMI as a comparison analysis, given the
association that exists with the dietary patterns. We report percent change in phthalate
biomarkers per one standard deviation increase in total dietary score, calculated as the
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exponentiated beta subtracted from one and multiplied by 100 and 95% confidence
intervals (CIs).
All analyses were performed using Stata version 16.0 (Stata Corporation LLC,
College Station, TX).
3.3

Results
Characteristics of the study population at baseline stratified by tertiles of the

dietary pattern scores are presented in Table 3.1. Briefly, we observed that, compared to
those in the third tertile, women in the first tertile of the DASH and aMed diet scores
were younger (61 years, SD 6.6; 61 years, SD 6.8), more likely to be from the Northeast
(193,40.4%; 206, 41.7%), and had a higher BMI (29.05 kg/m2, SD 6.1; 28.22 kg/m2,
SD5.7). Conversely, compared to those in the third tertile, women in the first tertile of the
DII score were older (63 years, SD 6.7), more likely to be from the West (178, 44.6%),
and had a lower BMI (26.85 kg/m2, SD 5.0).
Geometric mean concentrations of urinary phthalate biomarkers, adjusted for age,
creatinine, and region, are presented in Table 3.2. In general, urinary phthalate biomarker
concentrations were higher among women in the first tertile of the DASH and aMed diet
scores and lower for women in the first tertile of the DII score. The observed associations
were statistically significant for MBzP, MCNP, MCOP, MCPP, MEP, and ΣDEHP.
Table 3.3 reports estimated multivariable-adjusted associations of DASH, aMed,
and DII standardized scores with phthalate biomarkers. The DASH dietary score was
significantly inversely associated with MBzP (-6.89%, 95% CI -10.59, -3.03), MCPP (3.45%, 95% CI -6.60, -0.20), MEP (-7.56%, 95% CI -12.14, -2.73), and ΣDEHP (-6.48%,
95% CI -9.84, -3.00) concentrations. DASH dietary score was not significantly associated
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with MCOP, MCPP, ΣDBP, or ΣDiBP concentrations. Similarly, the aMed dietary score
was inversely associated with MBzP (-8.71%, 95% CI -12.40, -4.87), MCPP (-3.99%,
95% CI -7.19, -0.67), ΣDEHP (-5.23%, 95% CI -8.73, -1.60), and ΣDBP (-4.16%, 95%
CI -8.11, -0.03) concentrations. aMed dietary score was not associated with MCOP,
MCPP, MEP, or ΣDiBP concentrations. DII scores were significantly positively
associated with concentrations of MBzP (8.03%, 95% CI 3.77, 12.48), MCOP (3.77%,
95% CI 0.13, 7.56) ΣDEHP (8.83%, 95% CI 4.91, 12.89), ΣDBP (6.47%, 95% CI 2.18,
10.94) and ΣDiBP (4.46%, 95% CI 0.56, 8.52); no statistically significant associations
were observed between DII score and MCNP, MCOP, MCPP, or MEP concentrations.
Lastly, for comparison, we adjusted models for BMI, presented in supplemental Table 1,
and saw a slight attenuation of the measure of association in all dietary patterns.
However, the attenuation was minimal, and there was no change to the statistical
significance.
3.4

Discussion
Among a large sample of postmenopausal women, we observed significantly

lower urinary concentrations of MBzP, MCPP, MEP, ΣDBP, and ΣDEHP associated with
higher alignment with the DASH and Mediterranean diets. Additionally, we also
observed significantly higher concentrations of MBzP, ΣDEHP, ΣDBP, and ΣDiBP
associated with higher DII scores, which are indicative of pro-inflammatory potential
from dietary intake. Higher DASH scores were associated with lower MEP
concentrations, yet the Mediterranean diet and DII scores were not associated with MEP.
No associations were observed between MCNP, MCOP, and the dietary pattern scores.
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We did not adjust for BMI in our final multivariable models, given the
relationship that exists between dietary patterns and BMI (i.e., positive associations
between type of diet consumed and BMI). We concluded that adjustment for BMI would
result in an over adjustment provided that the DASH and Mediterranean diets have been
associated with lower BMI. (65–68,71–74,93–95) Note, when models were adjusted for
BMI, we observed some attenuation in the results, although it was not substantial. Thus,
we did not include BMI in our final multivariable models. Overall, consumption of
better-quality diets was related to statistically significantly lower concentrations of
phthalates, specifically those commonly used in food packaging material (e.g., DEHP and
DBP).
Notably, higher consumption of whole fruits and vegetables, legumes, whole grains,
nuts, and unsaturated fats, which result in higher Mediterranean and DASH scores and
lower DII scores, are also foods that are less likely to be processed or packaged in plastic.
(68,71,73,84) While foods that align with the modern interpretations of the DASH and
Mediterranean diets may still be prepacked, phthalate contamination of those foods may
be lower, given that the lipophilic characteristics of phthalates make the chemicals more
likely to “stick” to foods high in fat. (19,24,46,47) Recent studies reporting highfat/processed foods, plastic-bottled beverages, and foods in plastic packaging contained
the highest levels of DBP and DEHP. (51,52,58,96) These findings are consistent with
our observed negative associations between higher alignment with the DASH and
Mediterranean diets and urinary concentrations of ΣDBP and ΣDEHP, and positive
associations between higher DII scores and urinary concentrations of ΣDBP and ΣDEHP.
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Our study results were also consistent with current human studies. We observed
lower concentrations of phthalates with decreased consumption of meat and meat
products, milk and milk products, and cheese, key food groups that result in a lower
Mediterranean diet score. We also observed higher concentrations of phthalates with
higher DII scores, which result from higher consumption of red and processed meats,
sweetened beverages, and refined carbohydrates. (83) DEHP concentrations were
significantly lower with closer conformance of both the DASH and Mediterranean diets
and significantly higher with higher DII scores indicative of a pro-inflammatory diet;
DEHP has been positively associated with consumption of fast food, food not prepared at
home, processed and ultra-processed foods. (54,57,59) These are also foods that are more
commonly packaged, a leading source of contamination. (18,19,24,46–48) Additionally,
MCPP concentrations were statistically lower with higher DASH and Mediterranean diet
scores, consistent with previous studies showing increased concentrations with higher
consumption of processed and ultra-processed foods. (55,59,60) Lastly, our findings are
consistent with a small pilot study that reported lower urinary phthalate biomarker
concentrations after consuming a vegetarian diet for five consecutive days versus before
the intervention period. (97)
Our results suggest that consumption of pro-inflammatory diets is also associated
with higher exposure to phthalates common in plastic-packaged foods, including DEHP
and DBP. The literature on inflammation and phthalate biomarkers is inconsistent, yet a
studies have found higher phthalate exposure was associated with higher levels of proinflammatory biomarkers such as interleukin 6 (IL6) and C-reactive protein (CRP),
specifically among individuals who reported higher consumption of processed and high-
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fat foods. (19,24,44,46,47)However, the association between phthalate and inflammatory
biomarkers is inconsistent in the current literature. In studies evaluating the association
between urinary phthalate biomarkers and serum markers of inflammation, MBzP, monoisobutyl phthalate (MiBP), and DEHP were positively associated with higher CRP, IL-6,
and TNF-α levels but not associated with alkaline phosphate (ALP), absolute neutrophil
count (ANC), indicators of higher inflammation. (44,98–100)
We observed that lower MEP concentration was significantly associated with higher
alignment with the DASH diet yet was not associated with higher alignment with the
Mediterranean diet. While these two dietary scores are positively correlated, they have
important differences. (101) For example, meat consumption is consistent with adherence
to the DASH diet yet is rare among those following the Mediterranean diet. MEP is a
metabolite of DEP, a phthalate biomarker with some use in food packaging and
meat/meat products since the 1980s. (102) Thus, the association of DASH scores with
urinary MEP concentrations may be reflective of higher meat consumption. Alternatively,
the lack of association between aMed score and MEP may reflect the narrower range of
aMed (0-9) compared to the DASH diet (8-40), which lowers available statistical power.
Our results must be interpreted within the context of the study’s limitations. Because
dietary consumption was self-reported using FFQs, our study has the potential for nondifferential exposure misclassification. However, the FFQ measurement characteristics
have been published and shown to have a high correlation (0.89) to the gold standard (24h recalls and food diaries). Thus any non-differential misclassification would be minimal
and would bias results toward the null. (103) Our study also had the potential for nondifferential misclassification of the outcome. Because phthalate biomarkers have a short
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half-life, there is variability in the metabolites, which could result in within-person
variability and attenuate the results. Additionally, there is a potential for type I error,
given the large number of statistical comparisons performed. However, the general
consistency of our findings across dietary scores and with prior literature supports the
validity of our findings.
Our study is strengthened by the availability of a large, well-characterized sample of
women. Also, we quantified a broad panel of phthalate metabolites in first-morning void
urine samples using an established analytic method with proven reliability and validity.
The repeated measures of phthalate biomarkers and evaluation of dietary patterns versus
individual food groups are notable and a unique aspect of our study. Although we found
compelling results suggesting lower urinary phthalate concentrations with higher
alignment to healthy dietary patterns (i.e., DASH and Mediterranean diet), it is a crosssectional study. Therefore, temporality and causality cannot be established, and results
should be interpreted cautiously.
We observed that closer alignment with dietary patterns promoting the consumption
of whole vegetables and fruits were associated with lower concentrations of phthalate
biomarkers. Moreover, these findings may call for careful consideration of the potential
for confounding by dietary patterns when examining potential associations between
phthalate exposure and health outcomes.
Alignment with the DASH diet, Mediterranean diet, or a diet with low DII scores
provides several benefits and may present a non-invasive means of lowering phthalate
exposure. Our results suggest that phthalates leaching from plastic packaging have a
higher affinity for high-fat and processed foods, resulting from their lipophilic
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characteristics. Therefore, individuals who generally consume high-fat or processed
foods have higher phthalate concentrations. However, further research is needed to
explore and confirm the exact mechanisms linking phthalate exposure and dietary
patterns to health outcomes.
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3.5

Chapter 3 Tables

Table 3.1. Descriptive characteristics, at baseline, of study group, stratified by tertiles of dietary pattern scores, N=1,240
Characteristics1

DASH Diet Score

aMed Diet Score

DII Diet Score

T:<=22
T3:>=28
P value
T1:<=3
T3:>=9
P value
T1:<=-3.49
T3:>=4.54
P value
Age; Mean (SD)
61.17 (6.66)
63.97 (6.92)
<0.001
61.81 (6.83)
63.41 (6.95)
0.007
63.89 (6.73)
60.74 (6.78)
<0.001
Region; N (%)
<0.001
0.141
<0.001
Northeast
193 (40.4)
125 (39.6)
206 (41.7)
94 (36.0)
138 (34.6)
181 (41.6)
South
151 (31.6)
59 (18.7)
132 (26.7)
60 (23.0)
83 (20.8)
132 (30.3)
West
134 (28.0)
132 (41.8)
156 (31.6)
107 (41.0)
178 (44.6)
122 (28.0)
BMI (kg/m2); Mean (SD)
29.05 (6.11)
27.34 (5.42)
<0.001
28.22 (5.70)
27.74 (5.90)
0.540
26.85 (5.05)
29.55 (6.34)
<0.001
Education status; N (%)
<0.001
<0.001
<0.001
Less than high school degree
178 (37.2)
51 (16.1)
175 (35.4)
33 (12.6)
80 (20.1)
145 (33.3)
Post high school/some college
185 (38.7)
105 (33.2)
188 (38.1)
85 (32.6)
140 (35.1)
168 (38.6)
College degree or higher
115 (24.1)
160 (50.6)
131 (26.5)
143 (54.8)
179 (44.9)
122 (28.0)
Income; N (%)
<0.001
<0.001
<0.001
Less than $34,999
257 (56.7)
125 (41.7)
260 (55.1)
98 (40.2)
149 (39.3)
235 (56.5)
Greater than $35,000
196 (43.3)
175 (58.3)
212 (44.9)
146 (59.8)
230 (60.7)
181 (43.5)
Alcohol intake, drinks/wk; N (%)
<0.001
<0.001
0.003
0 drinks/week
184 (38.5)
89 (28.2)
179 (36.2)
63 (24.1)
111 (27.8)
153 (35.2)
<1 drink/week
176 (36.8)
110 (34.8)
195 (39.5)
72 (27.6)
132 (33.1)
164 (37.7)
1-6 drinks/week
83 (17.4)
90 (28.5)
75 (15.2)
101 (38.7)
119 (29.8)
77 (17.7)
7+ drinks/week
35 (7.3)
27 (8.5)
45 (9.1)
25 (9.6)
37 (9.3)
41 (9.4)
Smoking status; N (%)
<0.001
<0.001
<0.001
Never Smoked
271 (57.7)
178 (56.7)
278 (57.0)
135 (52.5)
225 (57.0)
231 (53.8)
Past Smoker
150 (31.9)
131 (41.7)
163 (33.4)
116 (45.1)
160 (40.5)
154 (35.9)
Current Smoker
49 (10.4)
5 (1.6)
47 (9.6)
6 (2.3)
10 (2.5)
44 (10.3)
Total physical activity, MET-hr/wk,
quartiles; N (%)
<0.001
<0.001
<0.001
≤1.87
146 (35.9)
48 (16.6)
146 (34.2)
38 (16.2)
61 (16.4)
135 (37.1)
>1.92-7.5
112 (27.5)
62 (21.5)
111 (26.0)
60 (25.5)
91 (24.4)
101 (27.7)
>7.75-16.6
82 (20.1)
74 (25.6)
91 (21.3)
51 (21.7)
107 (28.7)
62 (17.0)
>16.75
67 (16.5)
105 (36.3)
79 (18.5)
86 (36.6)
114 (30.6)
66 (18.1)
Dietary Energy (kcal); Mean (SD)
1656.6 (751.5)
1687.1 (634.4)
0.812 1434.3 (622.9) 2018.5 (747.0)
<0.001 1419.6 (493.9) 1910.8 (819.4)
<0.001
Dietary Animal Protein (g); Mean (SD)
49.0 (25.1)
49.4 (26.3)
0.975
42.3 (20.2)
58.1 (28.4)
<0.001
41.6 (18.7)
55.8 (29.0)
<0.001
Dietary Vegetable Protein (g); Mean (SD)
17.6 (7.9)
24.9 (9.1)
<0.001
15.7 (7.0)
28.1 (9.0)
<0.001
20.6 (8.5)
20.4 (8.9)
0.344
Abbreviations: MET, metabolic equivalent; DASH, Dietary Approach to Stop Hypertension; aMed, Alternative Mediterranean Diet; DII, Dietary Inflammation Index; BMI, Body Mass Index
1
Missing data are as follows: BMI, n=8; income, n=65; smoking, n=15; physical activity n=145; dietary energy, n=1; dietary animal protein, n=1; dietary vegetable protein, n=1
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Table 3.2. Adjusted means of phthalate biomarkers, stratified by tertiles of dietary pattern scores, N=1,2401
DASH Diet Score

aMed Diet Score

DII Diet Score

1st Tertile
3rd Tertile
1st Tertile
3rd Tertile
1st Tertile
3rd Tertile
<=22
>=28
<=3
>=9
<=-3.49
>=4.54
Phthalate Biomarker
Geometric Mean (SD)
P value
Geometric Mean (SD)
P value
Geometric Mean (SD)
P value
MBZP, ng/mL
13.41 (2.93)
8.83 (3.03)
0.001
12.85 (2.98)
9.49 (3.10) <0.001
8.95 (2.89)
14.61 (2.87) <0.001
MCNP, ng/mL
2.96 (2.34)
2.59 (2.79)
0.56
2.91 (2.38)
2.97 (2.87)
0.02
2.67 (2.73)
3.23 (2.33)
0.93
MCOP, ng/mL
4.21 (2.45)
3.28 (2.77)
0.20
4.10 (2.52)
3.52 (2.73)
0.33
3.31 (2.58)
4.58 (2.42)
0.01
MCPP, ng/mL
3.42 (2.45)
2.63 (2.55)
0.16
3.40 (2.48)
2.83 (2.56)
0.05
2.73 (2.47)
3.73 (2.40)
0.17
MEP, ng/mL
97.00 (3.54)
56.81 (3.35) <0.001
86.71 (3.39)
66.63 (3.43)
0.05
71.48 (3.57)
94.63 (3.55)
0.86
ΣDEHP, µmol/L
0.21 (2.58)
0.15 (2.61) <0.001
0.20 (2.63)
0.16 (2.69)
0.004
0.15 (2.66)
0.23 (2.52) <0.001
ΣDBP, µmol/L
0.13 (3.00)
0.09 (3.23)
0.54
0.13 (2.96)
0.11 (3.23)
0.25
0.10 (3.02)
0.15 (2.99)
0.08
ΣDiBP, µmol/L
0.01 (2.83)
0.01 (2.76)
0.47
0.01 (2.75)
0.01 (2.85)
0.88
0.01 (2.84)
0.02 (2.77)
0.13
Abbreviations: DASH, Dietary Approach to Stop Hypertension; aMed, Mediterranean Diet; DII, Dietary Inflammatory Index; MBzP, monobenzyl phthalate; MCNP,
mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl)
phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Geometric means estimated from regression models adjusted for age, creatinine, and region
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Table 3.3. Multivariable adjusted associations between standardized dietary scores and percent change in phthalate biomarkers, N=1,2401
DASH Diet Score2
aMed Diet Score2
Energy-adjusted DII Score2
Phthalate Biomarker
% Change (95% CI)
P value
% Change (95% CI)
P value
% Change (95% CI)
P value
MBZP
-6.89 (-10.59, -3.03)
<0.001
-8.71 (-12.40, -4.87)
<0.001
8.03 (3.77, 12.48)
<0.001
MCPP
-3.45 (-6.60, -0.20)
0.04
-3.99 (-7.19, -0.67)
0.02
2.40 (-0.95, 5.86)
0.16
MCNP
0.66 (-2.90, 4.34)
0.72
2.80 (-0.96, 6.70)
0.15
1.21 (-2.42, 4.97)
0.52
MCOP
-2.13 (-5.53, 1.40)
0.23
-1.34 (-4.89, 2.33)
0.47
3.77 (0.13, 7.56)
0.04
MEP
-7.56 (-12.14, -2.73)
<0.001
-1.72 (-6.65, 3.47)
0.51
1.56 (-3.43, 6.81)
0.55
ΣDEHP
-6.48 (-9.84, -3.00)
<0.001
-5.23 (-8.73, -1.60)
0.01
8.83 (4.91, 12.89)
<0.001
ΣDBP
-3.75 (-7.64, 0.31)
0.07
-4.16 (-8.11, -0.03)
0.05
6.47 (2.18, 10.94)
<0.001
ΣDiBP
-2.29 (-6.00, 1.57)
0.24
-1.54 (-5.30, 2.37)
0.43
4.46 (0.56, 8.52)
0.02
Abbreviations: DASH, Dietary Approach to Stop Hypertension; aMed, Alternate Mediterranean; DII, Dietary Inflammatory Index; MBzP,
monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl
phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Adjusted for creatinine, age, region, education level, alcohol consumption, dietary energy, dietary animal protein
2 Total dietary scores were z-score standardized
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Table 3.4. Multivariable adjusted associations between standardized dietary scores and percent change in phthalate biomarkers, N=1,2401
Phthalate Biomarker

DASH Diet Score2

aMed Diet Score2

Energy-adjusted DII Score2

% Change (95% CI)
P-value
% Change (95% CI)
P-value
% Change (95% CI)
P-value
MBZP
-6.97 (-10.69, -3.09)
<0.001
-8.88 (-12.57, -5.02)
<0.001
7.55 (3.27, 12.01)
<0.001
MCPP
-3.32 (-6.50, -0.03)
0.05
-3.99 (-7.21, -0.65)
0.02
2.05 (-1.31, 5.53)
0.24
MCNP
1.12 (-2.45, 4.83)
0.54
2.98 (-0.79, 6.89)
0.12
0.56 (-3.06, 4.32)
0.76
MCOP
-1.60 (-5.04, 1.96)
0.37
-1.22 (-4.77, 2.47)
0.51
2.96 (-0.67, 6.73)
0.11
MEP
-7.22 (-11.83, -2.37)
<0.001
-1.92 (-6.85, 3.26)
0.46
1.06 (-3.92, 6.29)
0.68
ΣDEHP
-5.93 (-9.32, -2.41)
<0.001
-4.74 (-8.27, -1.08)
0.01
7.89 (3.98, 11.95)
<0.001
ΣDBP
-3.93 (-7.85, 0.14)
0.06
-4.34 (-8.31, -0.20)
0.04
6.59 (2.26, 11.10)
<0.001
ΣDiBP
-2.40 (-6.14, 1.48)
0.22
-1.59 (-5.37, 2.35)
0.42
4.47 (0.53, 8.56)
0.03
Abbreviations: DASH, Dietary Approach to Stop Hypertension; aMed, Alternate Mediterranean; DII, Dietary Inflammatory Index; MBzP, monobenzyl phthalate;
MCNP, mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP,
di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Adjusted for creatinine, age, region, education level, alcohol consumption, dietary energy, dietary animal protein, BMI
2 Total dietary scores were z-score standardized
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CHAPTER 4
ASSOCIATION BETWEEN URINARY PHTHALATE BIOMARKER
CONCENTRATIONS AND ADIPOSITY AMONG POSTMENOPAUSAL
WOMEN
4.1

Introduction
The prevalence of obesity has nearly tripled worldwide over the last few decades,

becoming a global concern. (104,105) Adiposity is a leading risk factor for
cardiovascular disease (CVD), diabetes, cancer, and other chronic diseases. (106)(107),(108,109) Current literature shows that adiposity is strongly associated with
increased mortality for CVD and cancer (OR range 1.9-2.42). (109–112) Abdominal
adiposity is similarly strongly associated with the development of CVDs in adults
independent of body mass index (BMI). (112),(113) Although diet and physical activity
are key causal factors in obesity, endocrine-disrupting chemicals such as phthalates have
recently garnered attention as potentially contributing to the growing obesity epidemic.
(114–116)
Phthalates are synthetic man-made industrial compounds used to increase the
flexibility and durability of plastic products, specifically consumer products (e.g.,
medical devices, cosmetics, paints, shampoos, and cleaning materials). (18–23)
Phthalates follow a two-phase metabolism process, with the initial detoxication step
yielding bioactive metabolites that can disrupt normal lipid accumulation, adipogenesis,
and metabolic processes. (20,33,117,118) Importantly, phthalate metabolites may
activate peroxisome proliferator-activated receptors (PPAR). Phthalate metabolites have
the potential for bio-accumulation in fat reserves. (20,33,117,118) In vivo studies have
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shown that di(2-ethylhexyl) phthalate (DEHP) exposure over 10-weeks impaired insulin
sensitivity, increasing body weight and maladaptive adipose tissue function in female
mice. (119,120) Similarly, prenatal exposure to DEHP significantly increased body
weight and adipose tissue in male and female mice. (119,120)
Prior human studies reported positive associations between phthalates and
anthropometric measures of adiposity. Cross-sectional studies examining the associations
between phthalate biomarker exposure and BMI, waist circumference (WC), and weight
gain among males and females found positive associations; di-isobutyl phthalate (DiBP)
associated with increased BMI (kg/m2) (β=2.5, P<0.0009), mono-benzyl phthalate
(MBzP) and mono-isobutyl phthalate (MiBP) associated with increased WC (cm) (β=1.5,
P<0.0009; β=1.3, P=0.0043 ), DEHP associated with increased obesity prevalence (4th
vs. 1st quartile OR = 3.29, 95% CI 1.80–6.03), and MiBP associated with increased total
fat mass (β=1.79, P=0.0082). (121)-(92),(122) Prospective studies on the associations
between phthalate and adiposity are limited. However, two studies and a meta-analysis,
citing two prospective studies, evaluating the longitudinal association between phthalate
exposure, weight gain, and obesity among men and women observed consistent, albeit
weak, positive effects. Monoethyl phthalate (MEP) was positively associated with weight
gain per 3-year period (+ 2.32 kg [95% CI 0.93–3.72] for 4th vs. 1st quartile of MEP) and
MBzP with prospective weight gain per year (0.42 kg [95% CI 0.26–0.57] for 4th vs. 1st
quartile of MBzP). (92,123) Similarly, MBzP was associated with weight gain (.42 kg per
year [95% CI 0.26-0.57]) and, Mono(2-ethyl-5-hydroxyhexyl) phthalate (MECPP) was
positively associated with obesity among adults (OR=1.67, P=0.05). (111),(92,123)
However, prior human studies have primarily focused on relatively younger populations
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and have relied on BMI and WC measurements, which are imprecise measures of
adiposity, especially in older adults.
In older adults, adiposity can increase while body weight remains stable, resulting
from increased fat mass offset by decreased lean mass (i.e., adiposity increases and
muscle mass decreases), making the accurate measure of adiposity challenging. (124–
127) BMI cannot accurately distinguish between lean muscle mass and fat mass,
potentially leading to measurement error in assessing adiposity in older adults (i.e., an
individual with high central adiposity may present with a normal BMI). (128) Further,
BMI does not account for age-related decline in muscle mass observed among older
adults. (129)(130)-(131) This is especially problematic for assessing adiposity in older
women due to the age-related declines in height and skeletal muscle mass as well as the
redistribution of adipose tissue towards increased central adiposity. (132) Measures of
adipose tissue depots, namely visceral adipose tissue (VAT) and subcutaneous adipose
tissue (SAT), may provide a more sensitive and robust measurement of adiposity among
older adults. (133)
VAT and SAT have structural and functional differences. SAT, defined as the fat
beneath the skin, represents the normal physiological buffer or excess energy intake,
potentially indicative of a high-calorie diet with limited energy expenditure or low
physical activity. (134)-(135) SAT is commonly present around the abdominal and gluteal
regions, accounting for 80% of all body fat. (135) VAT, defined as fat that lines the
internal organs, is commonly present around the abdominal viscera in the mesentery and
omentum, accounting for about 20% of all body fat. (135)-(136) Relative to SAT, VAT is
more metabolically active, has greater lipolytic activity, and induces more elevated
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inflammatory responses. (134) Duel-energy X-ray absorptiometry (DXA) is a robust and
cost-effective method for assessing body composition, as it provides accurate estimates
of bone, fat, and lean soft tissue. (137) Although VAT and SAT have both been
associated with an increased risk of cardiovascular and metabolic diseases, (138,139) the
risk of disease differs between these forms of fat. For example, VAT has been more
strongly associated with: hypertension (OR=4.8 vs. 3.9), diabetes (OR=3.49 vs. 1.6), and
metabolic syndrome (OR=10.73 vs. 3.0), than SAT. (138–141)
Because prior studies have relied on BMI and WC to examine the association
with phthalate exposure, the true association between phthalates and adiposity is unclear.
Therefore, we provide the first evaluation of the associations between urinary phthalate
biomarker concentrations and DXA-derived measures of VAT and SAT among a sample
of participants in the prospective Women’s Health Initiative (WHI) cohorts.
4.2
4.2.1

Materials and Methods
Study Population
As previously described, the WHI recruited 161,808 postmenopausal women

from 40 clinical centers nationwide between October 1, 1993, and December 21, 1998.
(16) All participants were between the ages of 50 to 79 years at enrollment and
participated in one or more of the four clinical trials (CT; N=68,132) or an observational
study (OS; N=93,676). (16) Participants of a bone density substudy at three WHI sites
(Birmingham, AL; Pittsburgh, PA; Tucson/Phoenix, AZ) provided first-morning void
urine samples at baseline, annual visit (AV) 1 and AV3 (N=11,020) and were eligible for
inclusion in a nested case-control study of phthalate biomarkers and breast cancer
(N=1,257). (17) A total of 419 invasive breast cancer cases and 838 controls, 1:2 matched
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on enrollment date, length of follow-up, age at enrollment, and study arm, were selected.
(17) Only invasive breast cancer cases diagnosed after AV3 were included, to ensure that
urinary phthalate biomarkers were measured before breast cancer diagnosis. Participants
eligible for the present analysis met the following criteria: 1) had at least one urine
sample between baseline and AV3 and 2) had an adiposity measure between baseline and
AV6. Thus, our final analytic sample includes 1,011 participants.
Written informed consent was obtained from all participants upon their enrollment
into WHI, and approval was received from institutional review boards (IRB) at each WHI
clinical center. The University of Massachusetts Amherst IRB additionally approved the
present research. The involvement of the Centers for Disease Control and Prevention
(CDC) laboratory in the analysis of samples did not constitute an engagement in human
subjects’ research.
4.2.2

Quantification of Urinary Phthalate Metabolites
WHI followed a standard urine collection, processing, and storage protocol. First

morning void urine samples were collected at home and processed within 30 minutes
after clinic arrival. Urine samples were centrifuged for 5 minutes at 1330 x g; 1.8mL
aliquots were frozen and shipped to McKesson Bioservices packed in dry ice via
overnight FedEx then stored at -70°C.
Phthalate metabolites are used as biomarkers to ensure that measured
concentrations relate to endogenous exposures. The CDC quantified thirteen phthalate
metabolites in urine samples provided at baseline (mono-n-butyl phthalate [MBP],
monobenzyl phthalate [MBzP], MCNP, mono-carboxyoctyl phthalate [MCOP], MCPP,
mono(2-ethyl-5-carboxypentyl) phthalate [MECPP], mono-(2-ethyl-5-hydroxyhexyl)
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phthalate [MEHHP], mono-(2-ethylhexyl) phthalate [MEHP], mono(2-ethyl-5-oxohexyl)
phthalate [MEOHP], monoethyl phthalate [MEP], mono-hydroxybutyl phthalate
[MHBP], mono-hydroxyisobutyl phthalate [MHiBP], and monoisobutyl phthalate
[MiBP]). The glucuronidated phthalate metabolites undergo enzymatic deconjugation
followed by on-line solid phase extraction and high-performance liquid chromatographyelectrospray ionization-tandem mass spectrometry. Samples were randomly distributed
through the batches, with all replicates from cases and matched controls analyzed
together. A blinded 10% quality control sample was included and used to estimate CVs:
MBP 5.4%, MBzP 6.1%, MCNP 4.7%, MCOP 6.3%, MCPP 5.8%, MECPP 4.3%,
MEHHP 5.4%, MEHP 19.5%, MEOHP 6.0%, MEP 3.1%, MHBP 9.0%, MHiBP 21.9%,
MiBP 10.3%. Laboratory staff were masked to the identity, disease status, and
demographic and risk factor characteristics of the samples. Creatinine was measured
using a Roche Modular P Chemistry Analyzer (Indianapolis, IN) and an enzymatic assay.
The limit of detection (LOD) for creatinine was 1 mg/dL and the CV was 2.5%.(92),(91)
4.2.3

Adiposity Measurement
Adiposity was measured in participants of the WHI bone density substudy.

Participants underwent DXA measurements using Hologic machines (QDR2000, 2000+,
or 4500 Hologic) at baseline, AV3, and AV6 clinic visits. The historical DXA scans were
reanalyzed to measure VAT (cm2) and SAT (cm2). (142)-(143) Briefly, DXA-VAT and
DXA-SAT were measured in a 5-cm wide region placed across the entire abdomen above
the iliac crest at a level that approximately corresponds with the 4th lumbar vertebrae on
the whole-body DXA scan. The delimited lateral SAT on each side of the abdominal
cavity, measured via DXA, was used to model the anterior and posterior amount of SAT
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over the visceral cavity. (143)-(144) The estimated SAT over the visceral cavity was
added to the measured lateral SAT to calculate the total abdominal SAT. (144) The total
abdominal SAT was subtracted from the total abdominal fat measured via DXA to give
the estimated DXA-VAT. (143)-(144) DXA-derived measures of VAT and SAT have
demonstrated strong correlations with those measured by MRI (r=0.85 and r=0.83,
respectively). (143)
4.2.4

Covariate Data
Participants provided extensive data via self-reported questionnaires and at annual

clinic visits. We considered the following potential covariates all assessed at baseline,
with updates at subsequent clinic visits for time-varying covariates: age (continuous),
region (Northeast, South, West), education (less than high school, high school/some
college, college graduate, graduate degree), income (<$35,000, ≥$35,000), total physical
activity METs/week (quartiles), smoking status (never, past, current), current alcohol
intake (non-drinker, past drinker, <1 drink per month, <1 drink per week, 1-<7 drinks per
week, 7+ drinks per week), total caloric intake (continuous, kcal), hormone use status
(never, past, current), history of diabetes (yes, no), history of hypertension (yes, no),
Hormone Replacement Therapy trial arm (HT arm) (not randomized to HRT, E-alone
intervention, E-alone control, E+P intervention, E+P control), and Dietary Modification
trial arm (DM arm) (not randomized to DM, intervention, control). Note, we created an
indicator of hormone therapy use status (never, past, current) that incorporated HT trial
assignment and self-reported hormone therapy use.

40

4.2.5

Statistical analyses
Phthalate biomarker concentrations were natural log-transformed to improve

normality. Phthalate biomarkers were z-score standardized (i.e., each phthalate biomarker
was subtracted from their mean and divided by their respective standard deviation) and
analyzed as continuous and quartile variables. Sums of the metabolites of di-n-butyl
phthalate (ΣDBP), di-isobutyl phthalate (ΣDiBP), and di(2-Ethylhexyl) phthalate
(ΣDEHP) were calculated as the molar sum of ΣDBP from MBP and MHBP; ΣDiBP
from MiBP and MHiBP; ΣDEHP from MEHP, MEHHP, MEOHP, and MECPP. VAT
and SAT measures were analyzed continuously.
4.2.6

Cross-sectional Analyses
Generalized Estimating Equation (GEE) models were fit using the identity link

and Gaussian (normal) distribution to estimate cross-sectional associations between
phthalate biomarkers and DXA-VAT and DXA-SAT, using data from baseline through
AV3. For this analysis, we included individuals with at least one urinary phthalate
biomarker measurement and at least one adiposity measure (N=1,011). Initially, we fit a
single GEE model for each phthalate biomarker concentration, creatinine, age, and a
single covariate.
For the multivariable GEE model development, all variables from the single
predictor models, significant at the p<0.25 level, were included in our initial multiple
predictors model. In subsequent model selection, age, and creatinine, were retained in all
models regardless of statistical significance. In selecting our final multivariable model,
we utilized multiple criteria, including the significance of partial F-tests and changes of
10% in the magnitudes of the estimated regression coefficients; this yielded the following
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covariates for inclusion: creatinine, creatinine, age, region, education, smoking status,
physical activity, dietary energy intake, hormone therapy use, and DM arm.
4.2.7

Longitudinal Analyses
For the longitudinal analyses, we fit multilevel mixed-effects models to estimate

the associations of phthalate biomarkers with DXA-VAT and DXA-SAT. We analyzed
DXA-VAT and DXA-SAT as lead variables per 3-year intervals (i.e., DXA-VAT and
SAT measured at AV3 were the measures of the first 3-year interval, and DXA-VAT and
SAT at AV6 were the measures of the second 3-year interval). The 3-year intervals were
from baseline to year-3 and year-3 to year-6. We included individuals in the longitudinal
analyses if they had two urine samples and at least one measure of DXA-VAT or DXASAT (N=1,003). Controls each contributed up to two 3-year intervals (baseline to year-3
and year-3 to year-6), and cases contributed only a single 3-year interval (baseline to
year-3) to exclude the potential effects of cancer treatment on adiposity. As appropriate,
the phthalate measurement at the beginning of the 3-year interval was related to the
DXA-VAT or DXA-SAT measurement at the end of the respective interval.
Covariates for our final multivariable models were selected from the initial single
predictors model. Significance of partial F-tests and changes of 10% in the magnitudes of
the estimated regression coefficients were utilized in the final covariate selection,
yielding the following covariates: creatinine, age, region, smoking status, hormone use
status, and dietary energy.
All analyses were performed using Stata version 16.0 (Stata Corporation LLC,
College Station, TX). Two-sided P values less than or equal to 0.05 were considered
statistically significant.
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4.3

Results
Characteristics of the study population at baseline stratified by quartile of DXA-

VAT and DXA-SAT are presented in Tables 1A and 1B. Briefly, we observed that,
compared to those in the fourth quartile, women in the first quartile of DXA-SAT were
older (Q4 vs. Q1: 60 years, SD 6.32 vs. 63 years, SD 7.41, P < .0001). There was no
difference in age by quartiles of DXA-VAT. Women in the first quartile of DXA-VAT
were more likely to be from the Northeast (N=122) and have a lower BMI (23.2 kg/m2).
Similarly, women in the first quartile of DXA-SAT were more likely to be from the
Northeast (N=116) and have a lower BMI (22.9 kg/cm2).
Geometric mean concentrations of urinary phthalate biomarkers, adjusted for age,
creatinine, and region, are presented in Tables 2A and 2B. In general, urinary phthalate
biomarker concentrations were lower among women in the first quartile of DXA-VAT
and DXA-SAT.
Estimates of the multivariable-adjusted cross-sectional associations of measured
phthalates with VAT and SAT are reported in Table 3. We observed statistically
significant positive associations between MCOP (Q4 vs. Q1: β=7.66, 95% CI
0.95,14.36), MCPP (Q3 vs. Q1: β=6.79, 95% CI 0.71, 12.86), and ΣDEHP (Q4 vs. Q1:
β=9.12, 95% CI 2.06, 18.18) with VAT. No other measured phthalate was statistically
significantly associated with VAT. Additionally, we observed statistically significant
positive associations between MBzP (Q2 vs. Q1: β=9.31, 95% CI 0.16, 18.46), ΣDEHP
(Q3 vs. Q1: β=10.92 95% CI 1.27, 20.57), and ΣDBP (Q2 vs. Q1: β=8.98 95% CI -0.11,
18.07) with SAT. No other measured phthalate was statistically significantly associated
with SAT.
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Table 4 reports the estimated associations between urinary phthalate biomarker
concentrations and adiposity over a 3-year period. We observed a statistically significant
greater increase in VAT associated with higher concentrations of MCNP and ΣDiBP. For
example, compared to the first quartile, VAT increased by 10.49 cm2 among women with
MCNP concentrations in the fourth quartile (P trend=0.01) and 8.11 cm2 among women
with ΣDiBP concentrations in the fourth quartile (P trend=0.03). Similarly, higher
concentrations of MBzP (P trend=0.04) and ΣDiBP (P value=0.02) were associated with
a higher increase in SAT. Other phthalate biomarkers (MCOP, MCPP, MEP, ΣDEHP,
and ΣDBP) were not associated with VAT or SAT. However, when analyzed
continuously, ΣDEHP was positively associated with VAT (i.e., VAT increased 4.05 cm2
per one SD increase of ΣDEHP).
4.4

Discussion
In this prospective analysis of postmenopausal women, we observed higher urinary

concentrations of MCNP and ΣDiBP to be associated with increased VAT and higher
urinary concentrations of MBzP with increased SAT. In cross-sectional analyses, we
observed significantly higher VAT among women with the highest urinary concentrations
of MCOP, MCPP, and ΣDEHP and significantly higher SAT with higher urinary
concentrations of ΣDEHP. Notably, our study is the first to prospectively evaluate the
association between urinary phthalate biomarkers and DXA-derived VAT and SAT.
Our findings suggest that phthalate biomarker concentrations are more strongly
associated with VAT than SAT, consistent with prior studies evaluating adiposity,
measured via BMI and WC. A cross-sectional analysis within the US National Health and
Nutrition Examination Survey (NHANES) reported positive associations between MEHP
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and MEHHP, both major metabolites of DEHP, and higher BMI and WC (proxies of
adiposity) among females. (115) Similarly, MEHHP and MEOHP, major metabolites of
DEHP, were associated with increased odds of central obesity among females. (145)
Moreover, MBP, a major metabolite of DBP, was positively associated with general
obesity among females. (146) Longitudinal studies evaluating the associations between
phthalate biomarkers and adiposity are limited and have relied on imprecise measures,
including BMI and WC. However, our findings are consistent with two studies evaluating
the association between phthalate exposure and prospective weight gain. Diaz et al. found
increased weight gain associated with higher concentrations of MHiBP, a major
metabolite of DiBP, and MEOHP, a major metabolite of DEHP. (92) Similarly, Song et
al. found increased weight gain associated with higher concentrations of MBzP and
ΣDBP. (123) Note, our findings for the association between phthalates and SAT suggest a
non-linear association; statistically, associations were observed between SAT and certain
phthalate biomarkers (MBzP, ΣDEHP, and ΣDBP) when comparing quartile one with the
second and third quartiles only. This could result from phthalate biomarkers not
presenting with a typical dose-response curve; increased concentrations do not
necessarily correspond with an increase in effect (i.e., non-monotonic curves). (26)
It is difficult to determine why certain phthalate metabolites would be associated with
VAT and SAT, whereas others are not. Such associations may reflect common sources of
exposure and/or similar mechanisms of effects, such as activation of adipogenesis
through disruption of the PPAR-alpha (α) and gamma (γ). (120),(147)-(148)
Experimentally, MEHP, a major metabolite of DEHP, has been observed to activate
PPAR-α and γ, which our findings observed to be statistically associated with VAT and
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SAT. (125,149) Moreover, experimental data suggest that phthalates, observably DEHP,
act as ligands binding and activating PPAR-α and γ. (150–152) Compelling and growing
laboratory evidence also show that EDCs, including phthalates, may interfere with
regulatory metabolic processed and adipocyte function through altered lipid homeostasis
and promotion of adipogenesis. (112),(33), (148),(153) Note that the ligand role of
phthalates could be a possible explanation for the stronger association with VAT than
SAT, as VAT is more metabolically active. (134)
Our results must be interpreted in light of relevant limitations. Our study had the
potential for non-differential misclassification of the exposure. Because phthalate
biomarkers have a short half-life, there is within-person variability, attenuating the
results. Our study also had the potential for non-differential misclassification of the
outcome. Because DXA scans were performed by different operators at various clinical
sites, there is potential for protocol differences leading to differences in the measurement
of VAT and SAT. However, each site followed standard protocol, with central quality
assurance and control procedures, including cross-clinic calibration phantoms and review
of a random sample of scans. (154) Therefore, any non-differential misclassification
would be minimal and bias the results toward the null. Lastly, our study had the potential
for type I error, given the large number of statistical comparisons performed. However,
the general consistency of our findings across phthalate biomarkers and with prior
literature supports the validity of our findings.
Our study is strengthened by the availability of a large, well-characterized sample of
women. Also, we quantified a broad panel of phthalate metabolites in first-morning void
urine samples using an established analytic method with proven reliability and validity.
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Further, we utilized DXA-derived measures of VAT and SAT, a more robust and
accurate measurement that has been compared to the gold standards of adiposity (i.e.,
computer tomography [CT], and magnetic resonance imaging [MRI]) and shown to have
a high correlation (r2=0.95) and small average differences, 56 cm3. The repeated
measures of phthalate biomarkers and prospective evaluation of the association with
VAT and SAT are unique aspects of our study. Although we found compelling results
suggesting increased VAT and SAT with higher concentrations of certain phthalates (i.e.,
MCOP, MCPP, MCNP, ΣDEHP, and ΣDiBP), replication of our findings in other
prospective studies is needed.
Our findings represent the first prospective evaluation between urinary phthalate
biomarkers and DXA-derived VAT and SAT among an older population of
postmenopausal women. Our findings further suggest the need for and importance of
robust and accurate measures of adiposity that can differentiate between VAT and SAT.
Of specific importance given that VAT has been associated with a higher risk of
cardiometabolic disease and all-cause mortality among older women. Furthermore, our
findings observed a stronger association between phthalate biomarker concentrations and
increased VAT. Thus, given the ubiquity of phthalate exposures, even a modest increase
in excess VAT associated with phthalates could translate into increased adiposity-related
morbidity in older populations, further perpetuating the obesity epidemic.
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4.5

Chapter 4 Tables

Table 4.1. Descriptive characteristics, at baseline, of study group stratified by quartiles of VAT, N=1,011

Characteristics1
Age; Mean (SD)
Region; N (%)
Northeast
South
West
Education status; N (%)
Less than High school degree
Post high school/some college
College degree or more
Body Mass Index (kg/m2); Mean (SD)
Income; N (%)
Less than $34,999
Greater than $35,000

1st Quartile
<=110.0
62.0 (7.36)

Visceral Adipose Tissue, cm2
2nd Quartile
3rd Quartile
110.1-<=162.9
163.0-<=223.4
62.2 (6.81)
63.3 (6.70)

4th Quartile
>=223.5
62.4 (6.35)

122 (42.1)
50 (17.2)
118 (40.7)

98 (39.5)
67 (27.0)
83 (33.5)

100 (40.2)
66 (26.5)
83 (33.3)

109 (48.7)
45 (20.1)
70 (31.3)

55 (19.0)
88 (30.3)
147 (50.7)
23.2 (2.5)

62 (25.0)
82 (33.1)
104 (41.9)
26.5 (3.4)

81 (32.5)
102 (41.0)
66 (26.5)
29.8 (3.9)

67 (29.9)
91 (40.6)
66 (29.5)
34.5 (5.1)

115 (41.7)
161 (58.3)

107 (45.3)
129 (54.7)

120 (51.7)
112 (48.3)

127 (60.2)
84 (39.8)

Total physical activity, MET-hr/wk, quartiles; N (%)
≤1.87
44 (15.2)
57 (23.0)
75 (30.1)
78 (34.8)
>1.92-7.5
69 (23.8)
56 (22.6)
63 (25.3)
70 (31.3)
>7.75-16.6
85 (29.3)
67 (27.0)
56 (22.5)
37 (16.5)
>16.75
92 (31.7)
68 (27.4)
55 (22.1)
39 (17.4)
Smoking status; N (%)
Never Smoked
172 (59.3)
134 (54.0)
149 (59.8)
118 (52.7)
Past Smoker
101 (34.8)
99 (39.9)
86 (34.5)
98 (43.8)
Current Smoker
17 (5.9)
15 (6.0)
14 (5.6)
8 (3.6)
Alcohol intake, drinks/wk; N (%)
Non-drinker
35 (12.1)
27 (10.9)
34 (13.7)
40 (17.9)
Past drinker
35 (12.1)
46 (18.5)
58 (23.4)
55 (24.6)
<1 drink per month
35 (12.1)
26 (10.5)
36 (14.5)
32 (14.3)
<1 drink per week
68 (23.5)
61 (24.6)
46 (18.5)
40 (17.9)
1 to <7 drinks per week
84 (29.1)
64 (25.8)
54 (21.8)
42 (18.8)
7+ drinks per week
32 (11.1)
24 (9.7)
20 (8.1)
15 (6.7)
HT use Status; N (%)
Never use
110 (37.9)
110 (44.4)
132 (53.0)
129 (57.6)
Past user
37 (12.8)
32 (12.9)
31 (12.4)
34 (15.2)
Current user
143 (49.3)
106 (42.7)
86 (34.5)
61 (27.2)
Dietary Energy (kcal); Mean (SD)
1478.7 (554.6)
1627.1 (664.4)
1691.9 (759.8)
1850.5 (794.2)
Energy-adjusted DII; Mean (SD)
-2.8 (2.0)
-2.2 (2.1)
-1.9 (2.3)
-1.3 (2.5)
Abbreviations: MET, metabolic equivalent; HT, hormone therapy use status; BMI, body mass index, DII, dietary inflammatory index
1
Missing data are as follows: BMI, n=6; income, n=56; alcohol, n=2; dietary energy, n=1, Energy-adjusted Dietary Inflammatory Index, n=1
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P value
0.15
0.02

<0.001

<0.001
<0.001

<0.001

0.30

0.004

<0.001

<0.001
<0.001

Table 4.2. Descriptive characteristics, at baseline, of study group stratified by quartiles of SAT, N=1,011
Subcutaneous Adipose Tissue, cm2
2nd Quartile
3rd Quartile
292.2-<=370.6
370.7-<=466.7
62.7 (6.7)
63.1 (6.7)

1st Quartile
Characteristics1
<=292.1
Age; Mean (SD)
63.1 (7.41)
Region; N (%)
Northeast
116 (41.4)
94 (37.9)
100 (43.7)
South
50 (17.9)
58 (23.4)
55 (24.0)
West
114 (40.7)
96 (38.7)
74 (32.3)
Education status; N (%)
Less than High school degree
60 (21.4)
65 (26.2)
65 (28.4)
Post high school/some college
83 (29.6)
88 (35.5)
91 (39.7)
College degree or more
137 (48.9)
95 (38.3)
73 (31.9)
Body Mass Index (kg/m2); Mean (SD)
22.9 (2.15)
26.2 (2.4)
28.9 (2.9)
Income; N (%)
Less than $34,999
109 (41.1)
114 (48.1)
111 (51.6)
Greater than $35,000
156 (58.9)
123 (51.9)
104 (48.4)
Total physical activity, MET-hr/wk, quartiles; N (%)
≤1.87
43 (15.4)
61 (24.6)
66 (28.8)
>1.92-7.5
63 (22.5)
60 (24.2)
59 (25.8)
>7.75-16.6
77 (27.5)
64 (25.8)
54 (23.6)
>16.75
97 (34.6)
63 (25.4)
50 (21.8)
Smoking status; N (%)
Never Smoked
159 (56.8)
137 (55.2)
138 (60.3)
Past Smoker
103 (36.8)
94 (37.9)
80 (34.9)
Current Smoker
18 (6.4)
17 (6.9)
11 (4.8)
Alcohol intake, drinks/wk; N (%)
Non-drinker
28 (10.0)
35 (14.1)
30 (13.2)
Past drinker
38 (13.6)
45 (18.1)
49 (21.5)
<1 drink per month
34 (12.2)
30 (12.1)
29 (12.7)
<1 drink per week
67 (24.0)
52 (21.0)
52 (22.8)
1 to <7 drinks per week
82 (29.4)
58 (23.4)
56 (24.6)
7+ drinks per week
30 (10.8)
28 (11.3)
12 (5.3)
HT use status; N (%)
Never use
115 (41.1)
109 (44.0)
114 (49.8)
Past user
37 (13.2)
34 (13.7)
31 (13.5)
Current user
128 (45.7)
105 (42.3)
84 (36.7)
Dietary Energy (kcal); Mean (SD)
1489.9 (588.3)
1631.3 (661.3)
1650.5 (664.8)
Energy-adjusted DII; Mean (SD)
-2.7 (2.0)
-2.4 (2.1)
-2.0 (2.3)
Abbreviations: MET, metabolic equivalent; HT, hormone therapy use status; BMI, body mass index, DII, dietary inflammatory index
1
Missing data are as follows: BMI, n=6; income, n=56; alcohol, n=2; dietary energy, n=1, Energy-adjusted Dietary Inflammatory Index, n=1
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4th Quartile
>=466.8
60.9 (6.3)
119 (46.9)
65 (25.6)
70 (27.6)
75 (29.5)
101 (39.8)
78 (30.7)
35.1 (4.8)
135 (56.7)
103 (43.3)
84 (33.1)
76 (29.9)
50 (19.7)
44 (17.3)
139 (54.7)
107 (42.1)
8 (3.1)
43 (16.9)
62 (24.4)
36 (14.2)
44 (17.3)
48 (18.9)
21 (8.3)
143 (56.3)
32 (12.6)
79 (31.1)
1844.2 (838.2)
-1.2 (2.5)

P value
<0.001
0.02

0.001

<0.001
0.005
<0.001

0.35

0.01

0.01

<0.001
<0.001

Table 4.3. Adjusted means of phthalate biomarkers, at baseline, stratified by quartiles of VAT, N=1,011

Phthalate Biomarker
MBZP, ng/mL
MCNP, ng/mL
MCOP, ng/mL
MCPP, ng/mL
MEP, ng/mL
ΣDEHP, µmol/L
ΣDBP, µmol/L
ΣDIBP, µmol/L

1st Quartile
<=110.0
10.81 (9.75, 12.00)
2.74 (2.50, 3.00)
3.32 (3.02, 3.64)
3.12 (2.86, 3.40)
86.93 (75.92, 99.55)
0.16 (0.15, 0.17)
0.13 (0.12, 0.14)
0.011 (0.010, 0.013)

Visceral Adipose Tissue
2nd Quartile
3rd Quartile
110.1-<=162.9
163.0-<=223.4
Geometric Mean (95% CI)1
10.97 (9.81, 12.27)
13.27 (11.87, 14.84)
2.76 (2.50, 3.04)
2.97 (2.69, 3.27)
3.81 (3.44, 4.22)
4.49 (4.05, 4.97)
3.15 (2.88, 3.46)
3.59 (3.27, 3.93)
79.10 (68.36, 91.54) 95.14 (82.23, 110.07)
0.17 (0.16, 0.19)
0.20 (0.18, 0.22)
0.11 (0.10, 0.13)
0.14 (0.12, 0.16)
0.012 (0.011, 0.013)
0.014 (0.012, 0.015)

4th Quartile
>=223.5
12.48 (11.08, 14.05)
3.09 (2.78, 3.42)
4.57 (4.10, 5.09)
3.52 (3.19, 3.88)
79.61 (68.20, 92.92)
0.21 (0.19, 0.23)
0.12 (0.11, 0.13)
0.013 (0.011, 0.015)

Abbreviations: VAT, visceral adipose tissue; CI, confidence interval; MBzP, monobenzyl phthalate; MCNP, mono
carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP,
monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Geometric means estimated from regression models adjusting for age, creatinine, and region

Table 4.4. Adjusted means of phthalate biomarkers, at baseline, stratified by quartiles of adiposity, N=1,011

Phthalate Biomarker
MBZP, ng/mL
MCNP, ng/mL
MCOP, ng/mL
MCPP, ng/mL
MEP, ng/mL
ΣDEHP, µmol/L
ΣDBP, µmol/L
ΣDIBP, µmol/L

1st Quartile
<=292.1
10.57 (9.51, 11.75)
2.82 (2.57, 3.09)
3.41 (3.10, 3.76)
3.11 (2.85, 3.40)
88.36 (76.96, 101.43)
0.16 (0.15, 0.18)
0.12 (0.11, 0.14)
0.011 (0.010, 0.012)

Subcutaneous Adipose Tissue
2nd Quartile
3rd Quartile
292.2-<=370.6
370.7-<=466.7
Geometric Mean (95% CI)1
11.53 (10.31, 12.89)
13.01 (11.58, 14.62)
2.82 (2.56, 3.11)
2.91 (2.62, 3.22)
4.13 (3.73, 4.57)
4.12 (3.71, 4.59)
3.22 (2.93, 3.53)
3.53 (3.21, 3.88)
80.81 (69.82, 93.54) 87.91 (75.49, 102.36)
0.17 (0.16, 0.19)
0.203 (0.184, 0.223)
0.13 (0.11, 0.14)
0.13 (0.12, 0.15)
0.012 (0.011, 0.013)
0.014 (0.012, 0.015)

4th Quartile
>=466.8
12.40 (11.09, 13.86)
2.97 (2.69, 3.27)
4.36 (3.94, 4.83)
3.50 (3.19, 3.83)
83.69 (72.33, 96.84)
0.20 (0.181, 0.22)
0.12 (0.11, 0.14)
0.013 (0.011, 0.014)

Abbreviations: SAT, subcutaneous adipose tissue; CI, confidence interval; MBzP, monobenzyl phthalate; MCNP,
mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate;
MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Geometric means estimated from regression models adjusting for age, creatinine, and region
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Table 4.5. Cross-sectional associations between phthalate biomarkers and adiposity, N=1,011
Phthalate biomarker
MBZP, ng/mL
Q1: .21-5.9
Q2: 6.0-11.8
Q3: 11.9-22
Q4: 22.1-3590
P trend
MCNP, ng/mL
Q1: .14-1.6
Q2: 1.7-2.6
Q3: 2.7-4.7
Q4: 4.8-500
P trend
MCOP, ng/mL
Q1: .14-2.1
Q2: 2.2-3.6
Q3: 3.7-6.5
Q4: 6.6-1500
P trend
MCPP, ng/mL
Q1:.41-1.7
Q2: 1.8-3.0
Q3: 3.1-5.4
Q4: 5.5-271
P trend
MEP, ng/mL
Q1: .80-31.9
Q2: 32.0-68.1
Q3: 68.2-163
Q4: 164.0-26000
P trend
ΣDEHP, μmol/L
Q1: .007-.10
Q2: .11--.18
Q3: .181-.33
Q4: .331-68.5
P trend
ΣDBP, μmol/L
Q1: .002-.056
Q2: .059-.11
Q3: .111-.23
Q4: .231-28.16
P trend
ΣDiBP, μmol/L
Q1: .0018-.0061
Q2: .0062-.012
Q3: .013-.024
Q4: .025-4.01
P trend

Visceral Adipose Tissue, cm2
Beta (95% CI)1
P value

Subcutaneous Adipose Tissue, cm2
Beta (95% CI)1
P value

ref
5.28 (-0.52, 11.09)
5.28 (-1.03, 11.58)
4.80 (-2.50, 12.11)
0.21

0.07
0.10
0.20

ref
9.31 (0.16, 18.46)
2.49 (-7.46, 12.44)
1.48 (-10.05, 13.02)
0.95

0.05
0.62
0.80

ref
4.35 (-1.31, 10.01)
4.25 (-1.85, 10.36)
5.59 (-0.88, 12.06)
0.12

0.13
0.17
0.09

ref
6.61 (-2.30, 15.52)
6.48 (-3.12, 16.09)
6.36 (-3.82, 16.55)
0.27

0.15
0.19
0.22

ref
5.06 (-0.66, 10.79)
7.79 (1.67, 13.91)
7.66 (0.95, 14.36)
0.02

0.08
0.01
0.03

ref
5.06 (-3.97, 14.09)
7.04 (-2.62, 16.70)
6.13 (-4.44, 16.71)
0.26

0.27
0.15
0.26

ref
3.75 (-1.96, 9.46)
6.79 (0.71, 12.86)
6.56 (-0.65, 13.77)
0.04

0.20
0.03
0.07

ref
4.72 (-4.29, 13.72)
5.94 (-3.64, 15.52)
6.43 (-4.95, 17.82)
0.26

0.30
0.22
0.27

ref
-1.63 (-7.34, 4.07)
-1.83 (-8.04, 4.38)
-4.78 (-11.63, 2.06)
0.19

0.58
0.56
0.17

ref
2.12 (-6.87, 11.11)
0.44 (-9.35, 10.24)
1.59 (-9.23, 12.40)
0.86

0.64
0.93
0.77

ref
6.54 (0.81, 12.27)
7.19 (1.08, 13.30)
9.12 (2.06, 16.18)
0.02

0.03
0.02
0.01

ref
7.61 (-1.43, 16.66)
10.92 (1.27, 20.57)
10.49 (-0.65, 21.64)
0.05

0.10
0.03
0.07

ref
2.20 (-3.56, 7.97)
3.20 (-3.11, 9.52)
-1.24 (-8.57, 6.08)
0.86

0.45
0.32
0.74

ref
8.98 (-0.11, 18.07)
5.99 (-3.97, 15.96)
2.15 (-9.42, 13.72)
0.81

0.05
0.24
0.72

ref
4.77 (-1.00, 10.54)
3.46 (-2.92, 9.84)
3.85 (-3.78, 11.48)
0.37

0.11
0.29
0.32

ref
6.89 (-2.22, 15.99)
9.14 (-0.94, 19.22)
8.73 (-3.33, 20.79)
0.12

0.14
0.08
0.16

Abbreviations: MBzP, monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl
phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP,
di-n-butyl phthalate; DiBP, di-isobutyl phthalate; Ref, reference;
1Adjusted for creatinine, age, region, education, smoking, physical activity, dietary energy, hormone therapy use, and
dietary modification study arm
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Table 4.6. Longitudinal associations between phthalate biomarkers and adiposity, N=1,003
Visceral Adipose Tissue, cm2
Beta (95% CI)1
P value

Subcutaneous Adipose Tissue, cm2
Beta (95% CI) 1
P value

Phthalate biomarker
MBZP, ng/mL
Per 1 SD
2.60 (-0.56, 5.75)
0.11
4.56 (-0.37, 9.50)
0.07
Q1: .21-5.9
ref
ref
Q2: 6.0-11.8
1.03 (-5.63, 7.68)
0.76
6.36 (-4.06, 16.77)
0.23
Q3: 11.9-22
4.68 (-2.64, 12.01)
0.21
11.32 (-0.14, 22.77)
0.05
Q4: 22.1-3590
5.49 (-2.99, 13.97)
0.20
13.30 (0.03, 26.56)
0.05
P trend
0.15
0.04
MCNP, ng/mL
Per 1 SD
2.21 (-0.45, 4.87)
0.10
-0.06 (-4.25, 4.12)
0.98
Q1: .14-1.6
ref
ref
Q2: 1.7-2.6
8.04 (1.60, 14.49)
0.01
6.64 (-3.51, 16.80)
0.20
Q3: 2.7-4.7
7.14 (0.01, 14.27)
0.05
4.63 (-6.60, 15.87)
0.42
Q4: 4.8-500
10.49 (3.09, 17.90)
0.01
5.76 (-5.91, 17.43)
0.33
P trend
0.01
0.44
MCOP, ng/mL
Per 1 SD
1.81 (-1.10, 4.72)
0.22
1.16 (-3.39, 5.71)
0.62
Q1: .14-2.1
ref
ref
Q2: 2.2-3.6
-0.25 (-6.74, 6.24)
0.94
-3.84 (-13.98, 6.30)
0.46
Q3: 3.7-6.5
2.97 (-4.12, 10.06)
0.41
5.45 (-5.62, 16.53)
0.33
Q4: 6.6-1500
4.66 (-3.27, 12.59)
0.25
6.31 (-6.08, 18.71)
0.32
P trend
0.18
0.14
MCPP, ng/mL
Per 1 SD
1.50 (-1.56, 4.56)
0.34
2.62 (-2.17, 7.42)
0.28
Q1:.41-1.7
ref
ref
Q2: 1.8-3.0
2.72 (-3.71, 9.15)
0.41
1.97 (-8.12, 12.05)
0.70
Q3: 3.1-5.4
1.25 (-5.75, 8.25)
0.73
1.23 (-9.74, 12.19)
0.83
Q4: 5.5-271
4.09 (-4.34, 12.51)
0.34
5.73 (-7.46, 18.92)
0.39
P trend
0.46
0.47
MEP, ng/mL
Per 1 SD
-0.83 (-3.79, 2.12)
0.58
-1.61 (-6.23, 3.01)
0.50
Q1: .80-31.9
ref
ref
Q2: 32.0-68.1
-6.19 (-12.88, 0.50)
0.07
-10.27 (-20.76, 0.23)
0.06
Q3: 68.2-163
-6.71 (-13.96, 0.53)
0.07
-9.40 (-20.75, 1.96)
0.10
Q4: 164.0-26000
-2.69 (-10.57, 5.19)
0.50
-3.61 (-15.96, 8.74)
0.57
P trend
0.56
0.68
ΣDEHP, μmol/L
Per 1 SD
4.05 (1.04, 7.06)
0.01
3.37 (-1.34, 8.09)
0.16
Q1: .007-.10
ref
ref
Q2: .11--.18
3.30 (-3.44, 10.04)
0.34
4.41 (-6.16, 14.98)
0.41
Q3: .181-.33
2.62 (-4.33, 9.57)
0.46
4.27 (-6.63, 15.17)
0.44
Q4: .331-68.5
7.63 (-0.55, 15.81)
0.07
8.17 (-4.66, 21.00)
0.21
P trend
0.11
0.25
ΣDBP, μmol/L
Per 1 SD
-0.87 (-3.85, 2.11)
0.57
0.28 (-4.39, 4.96)
0.91
Q1: .002-.056
ref
ref
Q2: .059-.11
0.11 (-6.50, 6.71)
0.97
1.77 (-8.60, 12.14)
0.74
Q3: .111-.23
2.46 (-4.76, 9.69)
0.50
2.18 (-9.15, 13.51)
0.71
Q4: .231-28.16
-2.39 (-10.80, 6.02)
0.58
1.35 (-11.83, 14.54)
0.84
P trend
0.77
0.82
ΣDiBP, μmol/L
Per 1 SD
3.45 (0.04, 6.85)
0.05
2.27 (-3.06, 7.61)
0.40
Q1: .0018-.0061
ref
ref
Q2: .0062-.012
6.27 (-0.26, 12.80)
0.06
5.09 (-5.17, 15.36)
0.33
Q3: .013-.024
11.35 (4.05, 18.66)
0.00
13.46 (2.00, 24.93)
0.02
Q4: .025-4.01
8.11 (-0.79, 17.00)
0.07
8.36 (-5.59, 22.32)
0.24
P trend
0.03
0.10
Abbreviations: MBzP, monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP,
mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, diisobutyl phthalate;
1
Adjusted for creatinine, age, region, hormone therapy use status, smoking, dietary energy
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CHAPTER 5
PROSPECTIVE EVALUATION OF URINARY PHTHALATE BIOMARKER
CONCENTRATIONS AND ADJUDICATED CARDIOVASCULAR DISEASE
AMONG POSTMENOPAUSAL WOMEN
5.1

Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide,

accounting for 17.8 million deaths, an estimate expected to rise by more than 22.2.
million by 2030. (155),(156) CVD is an umbrella term that encompasses several
conditions (e.g., coronary artery disease, congestive heart failure, congenital heart
disease, stroke, arrhythmia, and atherosclerosis). (157),(158) In the United States (U.S.),
121.5 million adults have a form of CVD, with the estimate expected to rise to 130
million by 2035. (156),(159) CVD is strongly associated with older age, and women
specifically have a unique risk due to changing hormones. (160–162)
Age and sex are non-modifiable risk factors of CVD previously linked to the
deterioration of cardiovascular functionality, increasing the risk of CVD. (4–6)
Menopausal status has similarly been associated with increased risk of CVD, where the
decline in sex hormones (e.g., estrogen) may play a vital role. (5–7) For example,
estrogen may have a positive effect on the inner layer of the artery wall keeping blood
vessels flexible. (5–7) Further, other changes in the body after menopause (e.g., increased
blood pressure and cholesterol), coupled with modifiable risk factors (e.g., tobacco use,
education, low physical activity, alcohol consumption, and diet), may also have a role in
increasing the risk of CVD. (5–7) Notably, environmental toxicants, like phthalate
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biomarkers, are suggested to have a role in both the etiology and pathophysiology of
CVD as a result of ubiquitous exposure. (8–10)
Environmental factors have garnered increased attention as potentially significant
factors in CVD development. Prior animal studies found that phthalate exposure disrupts
normal cardiac function, the balance of lipid metabolism and increases oxidative stress,
increasing the risk of CVD development. (26,163,164) A systematic review of animal
studies reported that phthalate exposure, specifically di(2-Ethylhexyl) phthalate (DEHP),
has adverse effects on cardiomyocyte function in both chick embryos and rat offspring,
resulting in electro-physical changes like increased systolic blood pressure (BP), an
established risk factor for CVD. (165) A 20% increase in BP was also observed in the
offspring of mice mothers fed a phthalic diet during pregnancy. (26,163–165) Moreover,
cardiac hypertrophy increased with higher DEHP concentrations, resulting in elevated
BP. (26),(165) Phthalate exposure also significantly increased oxidative stress and
decreased antioxidant capacity of cardiac tissue related to vascular dysfunction. (163)
Although positive associations between phthalate exposure and CVD are observed in
animal studies, epidemiological study results have been less consistent.
Previous human studies reported positive associations between phthalates and CVD.
Cross-sectional studies examining the associations between phthalate exposure, risk
factors of CVD, and CVD among adults found positive associations; DEHP and dibutyl
phthalate (DBP) were positively associated with increased blood pressure (BP), a known
risk factor of CVD; mono-2-ethyl-5-oxohexyphthalate (MEOHP) and mono-2-ethyl-5carboxy-pentylphthalate (MECPP), major metabolites of DEHP, were positively
associated with diabetes mellitus (DM) and monomethyl phthalate (MMP), a major
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metabolite of DBP, was associated with increased odds of hyperlipidemia, established
risk factors of CVD; mono-isobutyl phthalate (MiBP), a major metabolite of (DiBP), and
mono-benzyl phthalate (MBzP) were associated with increased odds of total CVD. (166–
168) Similarly, a cross-sectional study on the association between phthalate exposure and
subclinical atherosclerosis, a primary underlying cause of CVD, in terms of carotid
intima-media thickness (CIMT) among a younger population observed increased odd of
thicker mean CIMT with increased concentration of DEHP (Q4 vs. Q1: OR=2.46,
p<0.001) and mono-n-butyl phthalate (MnBP) (Q4 vs. Q1: OR=2.80, p<0.001), a major
metabolite of DBP. (169,170) Lastly, one study evaluating the association between
phthalate metabolites and risk factors of CVD among an elderly population, 70 years and
older, found positive associations between MMP and low-density lipoprotein (LDL)
cholesterol (β=0.21, p=0.02). (171)
One case-control study among middle-aged males and females evaluating the
association between phthalate exposure and coronary heart disease (CHD) observed
approximately three-fold higher odds of CHD with greater concentrations of mono‐2‐
Ethylhexyl phthalate (MEHP), a metabolite of DEHP (Q3 vs. Q1: OR=2.77, 95% CI
1.22-6.28), MnBP (Q3 vs. Q1: OR=2.90, 95% CI 1.32-6.4), and MiBP (Q3 vs. Q1:
OR=3.19, 95% CI 1.41-7.21). (172)
Prospective studies on the association between phthalate biomarker exposure and
CVD are limited. One cohort study evaluating the association between phthalate
metabolites and subsequent risk of CVD mortality among participants of the National
Health and Nutrition Examination Survey (NHANES) 40 years and older found null
associations between all measured phthalates.(173) However, note that the risk of CVD
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mortality is an endpoint distinct from incident CVD. For example, CVD mortality is
more logistically challenging to adjudicate, requires a longer follow-up time, and cannot
evaluate the effect of exposure on disease onset. (174–176) Importantly, when using
mortality from CVD as an endpoint, individuals that potentially had CVD but did not die
from CVD are altogether missed. (174–176)
Notably, two systematic reviews of current epidemiological data concluded that
despite biological plausibility, current studies on the association between phthalate
exposure and risk of CVD have only presented weak and inconsistent associations.
(177,178) Current literature needs epidemiological studies that can establish a proper
sequence of exposure and outcome or prospective studies. (177,178) Therefore, we e
valuated the associations between urinary phthalate biomarker concentrations and
adjudicated cases of CVD among a subset of participants in the prospective Women’s
Health Initiative (WHI) cohorts.
5.2
5.2.1

Materials and Methods
Study Population
As previously described, the WHI recruited 161,808 postmenopausal women from

40 clinical centers nationwide between October 1, 1993, and December 21, 1998. (16)
All participants were between the ages of 50 to 79 years at enrollment and participated in
one or more of four clinical trials (CT; N=68,132) or an observational study (OS;
N=93,676). (16) Participants of a bone density substudy at three WHI sites (Birmingham,
AL; Pittsburgh, PA; Tucson/Phoenix, AZ) provided first-morning void urine samples at
baseline, annual visit (AV) 1, and AV3 (N=11,020) and were eligible for inclusion in a
previously conducted prospective nested case-control study of phthalate biomarkers and
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breast cancer (N=1,257). (17) A total of 419 invasive breast cancer cases and 838
controls, 1:2 matched on enrollment date, length of follow-up, age at enrollment, and
study arm, were selected. (17) Only invasive breast cancer cases diagnosed after AV3
were included, to ensure that urinary phthalate biomarkers were measured before
diagnosis. Participants eligible for the present analysis met the following criteria: 1)
available data on urinary phthalate metabolite concentrations measured at AV3, and 2)
free of CVD at AV3 (N=1,160).
Written informed consent was obtained from all participants upon their enrollment
into WHI, and approval was received from institutional review boards (IRB) at each WHI
clinical center. The University of Massachusetts Amherst IRB additionally approved the
present research. The involvement of the Centers for Disease Control and Prevention
(CDC) laboratory in the analysis of samples did not constitute an engagement in human
subjects’ research.
5.2.2

Quantification of Urinary Phthalate Metabolites
WHI followed a standard urine collection, processing, and storage protocol. First

morning void urine samples were collected at home and processed <30 minutes upon
clinic arrival. Urine samples were centrifuged for 5 minutes at 1330 x g; 1.8mL aliquots
were frozen and shipped to McKesson Bio-services packed in dry ice via overnight
FedEx then stored at -70°C.
Phthalate metabolites are used as biomarkers to ensure that measured
concentrations relate to endogenous exposures. The Personal Care Products Laboratory at
the Centers for Disease Control and Prevention quantified thirteen phthalate metabolites
in urine samples provided at baseline, AV1, and AV3 (mono-n-butyl phthalate [MBP],
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monobenzyl phthalate [MBzP], MCNP, mono-carboxyoctyl phthalate [MCOP], MCPP,
mono(2-ethyl-5-carboxypentyl) phthalate [MECPP], mono-(2-ethyl-5-hydroxyhexyl)
phthalate [MEHHP], mono-(2-ethylhexyl) phthalate [MEHP], mono(2-ethyl-5-oxohexyl)
phthalate [MEOHP], monoethyl phthalate [MEP], mono-hydroxybutyl phthalate
[MHBP], mono-hydroxyisobutyl phthalate [MHiBP], and monoisobutyl phthalate
[MiBP]). The glucuronidated phthalate metabolites undergo enzymatic deconjugation
followed by on-line solid phase extraction and high-performance liquid chromatographyelectrospray ionization-tandem mass spectrometry. Samples were randomly distributed
through the batches, with all replicates from cases and matched controls analyzed
together. A blinded 10% quality control sample was included and used to estimate CVs:
MBP 5.4%, MBzP 6.1%, MCNP 4.7%, MCOP 6.3%, MCPP 5.8%, MECPP 4.3%,
MEHHP 5.4%, MEHP 19.5%, MEOHP 6.0%, MEP 3.1%, MHBP 9.0%, MHiBP 21.9%,
MiBP 10.3%. Laboratory staff were masked to the identity, disease status, and
demographic and risk factor characteristics of the samples. Creatinine was measured
using a Roche Modular P Chemistry Analyzer (Indianapolis, IN) and an enzymatic assay.
The limit of detection (LOD) for creatinine was 1 mg/dL and the CV was 2.5%. (91)-(92)
5.2.3

Cardiovascular Disease Measurement
CVD was initially self-reported via questionnaires of the WHI CT and OS

participants, with additional information and documentation retrieved for the adjudication
process. CVD outcomes were adjudicated according to the WHI procedures for
ascertainment and adjudication of outcomes described elsewhere. (179) Briefly, WHI
followed a centralized adjudication process; upon outcome ascertainment, the
adjudication packet was assembled and scanned for electronic processing to the clinical
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coordinating center (CCC). CCC staff forwarded the adjudication case to a physician
adjudicator who completed the outcomes adjudication forms once the adjudication review
was complete. These forms were registered in the WHI database, and CCC staff
conducted final case quality assurance, and the case was then archived. (179)
For the current analyses, CVD cases were defined as incident, adjudicated cases of
myocardial infarction (MI) (n=31), coronary heart disease (CHD) (n=70), congestive
heart failure (CHF) (n=23), peripheral artery disease (PAD) (n=15), carotid artery disease
(CAD) (n=13), coronary revascularization (n=93), transient ischemic attack (TIA)
(n=10), heart valve disease (n=5), and angina (n=15).
5.2.4

Covariate Data
Participants provided extensive data via self-reported questionnaires and annual

visits (AV). We considered the following potential covariates assessed at baseline, with
updates at subsequent clinic visits for time-varying covariates: creatinine (continuous)
age (continuous), region (Northeast, South, West), body mass index (BMI) (continuous,
kg/m2), measured during annual clinic visits, income (<$35,000, ≥$35,000), education
(less than high school, high school/some college, college graduate, graduate degree),
smoking status (never, past, current), current alcohol intake (non-drinker, past drinker,
<1 drink per month, <1 drink per week, 1-<7 drinks per week, 7+ drinks per week), total
physical activity METs/week (quartiles), history of diabetes (yes, no), total caloric intake
(continuous), total fat intake (continuous), polyunsaturated fatty acids (continuous),
saturated fatty acids (continuous), dietary omega-3 (continuous), dietary omega-6
(continuous) dietary fiber (continuous), dietary animal protein (continuous), dietary
vegetable protein (continuous), history of hypertension (never hypertensive, untreated
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hypertensive, treated hypertensive), history of high cholesterol requiring pills (no, yes),
Dietary Approach to Stop Hypertension (DASH) diet (continuous), and the alternative
Mediterranean (aMed) diet (continuous). Hormone therapy (HT) use, previously defined,
included unopposed estrogen or estrogen + progesterone formulations. (180) HT use was
derived from reported medication use at clinic visits and mailed questionnaires and, when
applicable, HT trial intervention assignment. (180) We defined use across the 3-year
interval and considered women to be nonusers only if they did not report any use at
baseline or any follow-up during the 3-year interval.
5.2.5

Statistical Analysis
Phthalate biomarker concentrations were natural log-transformed to improve

normality. Phthalate biomarker were z-score standardized (i.e., each phthalate biomarker
was subtracted from their mean and divided by their respective standard deviation) and
analyzed as continuous and quartile variables. Sum of metabolites of di-n-butyl phthalate
(ΣDBP), di-isobutyl phthalate (ΣDiBP), and di(2-Ethylhexyl) phthalate (ΣDEHP) were
calculated as the molar sum of ΣDBP from MBP and MHBP; ΣDiBP from MiBP and
MHiBP; ΣDEHP from MEHP, MEHHP, MEOHP, and MECPP. CVD was analyzed
dichotomously, experienced failure event or did not (i.e., incident CVD).
For the present analyses, we defined AV3 as the study baseline. We used urinary
phthalate biomarker concentrations at baseline (AV3) for our primary analysis. In a
sensitivity analysis, we repeated analyses using the creatinine-standardized phthalate
biomarkers averaged across 2 to 3 measurements over three years. We began follow-up
and measurement of incident CVD at baseline (AV3) (Figure 1).
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Figure 5.1. Exposure collection period from baseline (AV3) on. Outcome collection
period baseline (AV3) on
5.2.6

Longitudinal Analyses
Cox proportional hazard regression models were fit to estimate the prospective

association between urinary phthalate biomarker concentrations and adjudicated CVD,
using data from baseline through AV3. Individuals contributed to follow-up time and
data until an adjudicated incident CVD event occurred, were censored, or the conclusion
of the study, whichever came first. Censoring events for the current analyses included
breast cancer diagnosis, death, or loss to follow-up. Breast cancer cases were censored
due to potential for cardiotoxic effects associated with treatment. (181)
Initially, we fit a single creatinine and age-adjusted Cox regression model for
each phthalate biomarker concentration and a single covariate. For the multivariable cox
regression model development, all variables from the single predictor models, significant
at the p<0.25 level, were included in our initial multiple predictors model. In subsequent
model selection, creatinine and age were retained in all models regardless of statistical
significance. In selecting our final multivariable model, we utilized multiple criteria,
including the significance of partial F-tests and changes of 10% in the magnitudes of the
estimated hazard ratio (HR) coefficients; this yielded the following covariates for
inclusion in our final multivariable model: creatinine, age, region, and HT use. In
addition, we conducted a sensitivity analysis evaluating the association between phthalate
exposure and CVD risk among controls only. Since controls were matched to breast
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cancer cases on key criteria, the sensitivity analyses served to show that risk was similar
despite the matching.
Because HT use has known negative effects on CVD (182–184), we a priori
decided to conduct additional stratified analyses on HT use. We repeated our similar
multivariable cox regression analysis, stratified on whether women used HT throughout
follow-up and adjusting for the same covariates. Lastly, we conducted a mediation
analysis adjusting for adiposity at the study baseline (AV3). Phthalates have been
associated with increased adiposity (92), (121)-(122) and increased adiposity is an
established risk factor of incident CVD. (185) Thus, we aimed to disentangle the effect
phthalate exposure has on CVD risk explained, directly or indirectly, by adiposity.
All analyses were performed using Stata version 16.0 (Stata Corporation LLC,
College Station, TX). Two-sided P values less than or equal to 0.05 were considered
statistically significant. (186)
5.3

Results
Characteristics of the study population, outlining contributed person-time and

total CVD per characteristic, are presented in Table 1. Briefly, the average age of
participants was 62 years (SD 6.9), and participants were more likely to be from the
Northeast (39%). Study participants were more likely to be never smokers (57%), have
an average BMI of 28.4 kg/m2 (SD 5.9), perform less than 7.5 metabolic equivalents
(MET) hours per week (26%), have no history of hypertension (68%), and no history of
high cholesterol requiring pills (88%).
Geometric mean concentrations of urinary phthalate biomarkers at study baseline
(AV3), and age-adjusted HRs, are presented in Table 2. Each phthalate contributed
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14,179 person-years and 123 adjudicated cases of CVD. In general, each urinary
phthalate had a wide dynamic range of concentrations, MEP had the highest geometric
mean, 68.7 ng/mL (SD 3.6), and MCNP had the lowest, 2.8 ng/mL (SD 2.5). Of the
calculated phthalate metabolite molar sums, ΣDEHP had the highest concentration, 0.2
µmol/L (SD 2.9).
Table 3 reports the multivariable-adjusted associations between urinary phthalate
biomarker concentrations, measured at AV3, and incident CVD among the full study
sample and controls only. We observed a statistically significant increase in CVD risk
associated with MEP among the full study sample and controls only. For example, in the
full-sample on the continuous scale, CVD risk increased by 28% per every 1 SD increase
in MEP (P=0.01). Similarly, among controls only on the continuous scale, CVD risk
increased by 26% for every 1 SD increase in MEP (P=0.03). We also observed a
statistically significant increase in CVD risk associated with increased concentrations of
ΣDEHP. Among controls only compared to the first tertile, CVD risk increased by 70%
among women with ΣDEHP concentrations in the second tertile (P=0.05). In the fullsample compared to the first tertile, CVD risk increased by 56%, although the association
was not statistically significant (P=0.06).
Table 4 reports the estimated associations between urinary phthalate biomarker
concentrations at AV3 and CVD stratified by HT use. We observed a statistically
significant increase in CVD risk among nonusers of HT associated with MEP (P=0.05).
For example, CVD risk increased by 36% per every 1SD increase in MEP. Likewise,
among users of HT, MEP was non-statistically significantly related to an increase in
CVD Risk (β=1.25, P=0.07). Similar associations were observed between higher
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concentrations of ΣDEHP and CVD risk among HT users and nonusers, although they
did not reach statistical significance (e.g., HT users Q2 vs. Q1: β=1.45, P=0.19; Nonusers
Q2 vs. Q1: β=1.76, P=0.18).
Table 5 reports the estimated associations between urinary phthalate biomarker
concentrations at AV3 and CVD adjusting for adiposity. We observed a statistically
significant increase in CVD risk associated with MEP (e.g., CVR risk increased by 26%
for every 1 SD increase in MEP, P=0.02). Lastly, overall results were similar when
analyses were repeated using creatinine-standardized urinary phthalate concentrations,
presented in Supplementary Table 1.
5.4

Discussion
In this prospective study of adjudicated CVD, we observed that women not using

HT experienced a greater increase in CVD risk associated with urinary concentrations of
MEP; no significant associations were observed among HT users. Similarly, increased
urinary concentrations of MEP and ΣDEHP were associated with increased risk of CVD.
Lastly, when adjusting the model for adiposity, the statistically significant association
between MEP concentrations and CVD risk persisted. Our results, despite limitations,
suggest that increased concentrations of certain phthalates increase CVD risk among
older postmenopausal women. This is of importance given the risk of CVD is highest in
older postmenopausal women, and phthalate exposure is ubiquitous.
Because prospective data on the effects of phthalates on CVD risk is lacking, it is
difficult to determine why certain phthalate metabolites were associated with CVD risk,
whereas others are not. These associations may reflect common sources of exposure (e.g.,
hair products, cosmetics, personal care products, and food packing) or mechanistic effects
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such as increased oxidative stress and vascular dysfunction. (26)(187–189) Additionally,
women have higher MEP concentrations than men. Notably, among HT users, we did not
observe any statistically significant associations between phthalate concentrations and
CVD risk, despite established increased CVD risk associated with HT use, as
demonstrated within the WHI population. (182–184) Provided that phthalates are far less
estrogenic than HT formulations, it is possible that HT-use masked any true effects of
phthalate exposure on CVD risk. These findings suggest that HT use may offer protection
against the deleterious effect of phthalate exposure; however, future work will be needed
to confirm these findings
Our study results are consistent with trends observed in cross-sectional studies
evaluating risk factors of CVD and self-reported CVD. For example, a cross-sectional
study within the NHANES, evaluating the association between urinary phthalates and
diabetes, a known risk factor for CVD, reported positive associations with increased
concentrations of MCPP and ΣDEHP. (190) Similarly, a cross-sectional analysis within
the population-based Prospective Investigation of the Vasculature in Uppsala Seniors
(PIVUS) study reported positive associations between MEP and increased blood pressure
(BP), a risk factor for CVD. (171) A cross-sectional analysis among Shanghai adults
observed positive associations between MEOHP, MECPP, and MEHHP, all major
metabolites of DEHP, and diabetes mellitus, a major risk factor of CVD. (168) Currently,
no human studies have prospectively evaluated the association between phthalate
biomarker concentrations and adjudicated incident CVD. However, one prospective study
within NHANES, evaluating the association between urinary phthalate exposure and
CVD mortality, reported null associations for all evaluated phthalates. (173) This study
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was limited in that it could not evaluate the effect of phthalate exposure on disease onset
and CVD mortality is a distinct endpoint from incident CVD.
This study and our findings must be considered in the context of relevant
limitations. Firstly, the observed HRs may reflect a type II error. Based on previously
conducted power calculations, we were aware that our study had limited power, 64.1%,
to detect a statistically significant association. Despite having reduced statistical power,
we observed statistically significant associations between increased phthalate biomarker
concentrations (e.g., MEP and ΣDEHP) and CVD risk. Our study may also have the
potential for residual confounding. For example, given the lack of longitudinal studies
evaluating the association between phthalate biomarkers and adjudicated CVD, there may
be confounding variables not yet identified that we did not include. However, we
adjusted for all relevant covariates and confounders identified a priori and through
purposeful model building.
The data used for these present analyses was a convenience sample. We utilized
data acquired from a nested case-control study (AS458) designed for a different outcome
to analyze the association with adjudicated CVD risk, posing some limitations (i.e.,
selection bias). Because participants were selected on the basis of having a later diagnosis
of breast cancer or were matched to breast cancer cases, the sample population may differ
from the underlying risk of CVD from the larger WHI bone mineral density (BMD)
Study Population. However, we compared BMD participants selected for AS458 to those
not selected on crucial characteristics, presented in Supplemental Table 2. We found that
these groups were of similar age, BMI, and HT trial arm, although AS458 participants
were somewhat more likely to be White (82.9% vs. 76.1%). Also, urinary phthalate
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samples were collected independently of CVD diagnosis. Lastly, we included women
selected as cases in our analysis, further increasing the potential for selection bias.
However, we repeated our analysis among women selected as controls to address this and
found similar results. Thus, we feel that selection bias did not substantially affect our
results. These analyses are primarily of an exploratory nature, and we have carefully
interpreted our results considering these limitations. Our work is a relevant preliminary
analysis to evaluate the feasibility of a larger, purposefully designed study of phthalates
and CVD risk. Lastly, our study had the potential for non-differential misclassification of
the exposure. Because phthalate biomarkers have a short half-life, there is variability in
the metabolites, which could result in within-person variability and attenuate the results.
However, this would bias the results toward the null.
Our study is strengthened by the prospective study design, which is a notable
improvement over prior cross-sectional studies. We further utilized adjudicated incident
cases of CVD, allowing for the evaluation of exposure effect on disease onset. Also, our
study focused on an older population of postmenopausal women for which CVD risk is
higher. (160,162,191,192) Moreover, our measured concentrations of urinary phthalate
metabolites were generally similar to those measured among the general United States
population. (193) Lastly, our study is novel in that it is the first, and to our knowledge,
the only study to prospectively evaluate the association between urinary phthalate
biomarker concentrations and adjudicated incident cases of CVD.
In summary, our results suggest that exposure to certain phthalates may be related
to increased risk of CVD; however, confirmation of these findings in future studies is
needed. Although our study is the most comprehensive and methodologically rigorous
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evaluation to date, it is a convenience sample. Future studies that prospectively evaluate
this association should be in a randomly selected and representative sample population.
Given the continued ubiquity of phthalates in consumer products, additional exploration
of the potential impact exposure has on CVD risk among an older postmenopausal
population will be advantageous in comprehensively understanding the risk profile of
these chemicals.
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5.5

Chapter 5 Tables

Table 5.1. Descriptive characteristics of the study population, presenting contributed person-time and CVD by characteristic, N=1,160
Characteristics
Age; Mean (SD)
Region; N (%)
Northeast
South
West
Smoking Status; N (%)
Never Smoked
Past Smoker
Current Smoker
Dietary Animal Protein (g); Mean (SD)
Hypertension; N (%)
Never hypertensive
Untreated hypertensive
Treated hypertensive
High cholesterol requiring pills; N (%)
No
Yes
Body Mass Index (kg/m2); Mean (SD)

Person-Years

Total CVD

HR (95% CI)1

62.5 (6.9)

14179

123

1.03 (1.01, 1.06)

462 (39.8)
295 (25.4)
403 (34.7)

5708
3428
5043

65
30
28

1.00
0.78 (0.50, 1.21)
0.47 (0.30, 0.73)

650 (56.9)
425 (37.2)
68 (5.9)
49.95 (25.81)

8244
5056
660
1668

62
46
10
32

1.00
1.26 (0.86, 1.85)
2.29 (1.16, 4.52)
1.01 (1.00, 1.03)

691 (68.6)
71 (7.1)
245 (24.3)

8537
831
2731

49
10
36

1. 00
2.12 (1.07, 4.19)
2.16 (1.39, 3.34)

878 (88.0)
120 (12.0)
28.4 (5.9)

10699
1293
14111

77
18
121

1.00
1.78 (1.06, 2.99)
1.04 (1.01, 1.07)

17
38
20
22

1.00
2.17 (1.22, 3.84)
1.26 (0.66, 2.41)
1.20 (0.63, 2.26)

111
12
55
32

1.00
2.24 (1.22, 4.09)
1.00 (1.00, 1.01)
1.11 (0.78, 1.59)

Total physical activity, MET-hr/wk, quartiles; N (%)
≤1.87
254 (24.9)
3083
>1.92-7.5
271 (26.5)
3095
>7.75-16.6
240 (23.5)
2869
>16.75
257 (25.1)
3248
History of Diabetes Ever; N (%)
No
1107 (95.6)
13550
Yes
51 (4.4)
593
Dietary Energy (kcal); Mean (SD)
1493.1 (617.6)
8220
Dietary Omega 3 (g); Mean (SD)
1.5 (1.1)
1668
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MET, metabolic equivalent; PFA, polyunsaturated fatty acid
1HR adjusted for age and creatinine
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Table 5.2. Geometric means of phthalate biomarkers and Age-adjusted HR, at AV3, N=1,160
Phthalate Biomarker1
Geometric mean (SD)
HR (95% CI)2
MBZP, ng/mL
9.8 (3.0)
0.99 (0.79, 1.24)
MCNP, ng/mL
2.8 (2.5)
0.99 (0.82, 1.22)
MCOP, ng/mL
3.6 (2.4)
1.05 (0.85, 1.29)
MCPP, ng/mL
2.7 (2.5)
1.06 (0.85, 1.31)
MEP, ng/mL
68.7 (3.6)
1.29 (1.07, 1.55)
ΣDEHP, µmol/L
0.2 (2.9)
0.96 (0.77, 1.18)
ΣDBP, µmol/L
0.1 (3.1)
0.96 (0.78, 1.20)
ΣDIBP, µmol/L
0.01 (2.9)
0.83 (0.66, 1.04)
Abbreviations: HR, hazard ratio; SD, standard deviation; CI, confidence interval; MBzP,
monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP, mono
carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl
phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl
phthalate
1Each phthalate biomarker contributed 14,179 person-years and 123 adjudicated cases of CVD
2HR adjusted for age and creatinine
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Table 5.3. Multivariable Cox regression analyses of the association between phthalate biomarkers at AV3, and adjudicated incident CVD,
N=1,160
Phthalate Biomarker at AV3
MBZP, ng/mL
Per 1 SD
Q1:0.21-6.7
Q2:6.8-15.3
Q3:15.4-489
P trend
MCNP, ng/mL
Per 1 SD
Q1:0.2-1.9
Q2:2.0-3.7
Q3:3.8-222
P trend
MCOP, ng/mL
Per 1 SD
Q1:0.2-2.5
Q2:2.6-5.1
Q3:5.2-270
P trend
MCPP, ng/mL
Per 1 SD
Q1:0.14-1.8
Q2:1.9-3.8
Q3:3.9-124
P trend
MEP, ng/mL
Per 1 SD
Q1:0.8-36.5
Q2:36.8-103
Q3:104-15900
P trend
ΣDEHP, μmol/L
Per 1 SD
Q1:0.009-0.124
Q2:0.125-0.271
Q3:0.272-68.47
P trend
ΣDBP, μmol/L
Per 1 SD

HR (95% CI)1
Full sample
N=1160

P value

1.04 (0.83, 1.31)
Ref
1.13 (0.71, 1.80)
1.21 (0.72, 2.04)
0.48

0.74

0.97 (0.79, 1.20)
Ref
0.80 (0.51, 1.26)
0.87 (0.53, 1.42)
0.57

0.81

1.02 (0.82, 1.26)
Ref
1.21 (0.76, 1.91)
1.09 (0.65, 1.83)
0.76

0.87

1.09 (0.87, 1.35)
Ref
0.92 (0.58, 1.45)
1.00 (0.60, 1.69)
1.00

0.45

1.28 (1.06, 1.55)
Ref
0.90 (0.56, 1.46)
1.40 (0.87, 2.25)
0.14

0.01

0.96 (0.78, 1.19)
Ref
1.56 (0.99, 2.47)
1.30 (0.76, 2.24)
0.34

0.73

1.00 (0.81, 1.24)

0.98

0.61
0.48

0.34
0.58

0.42
0.74

0.71
0.99

0.68
0.16

0.06
0.34
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HR (95% CI)2
Controls only
N=777

P value

1.08 (0.87, 1.34)
ref
1.03 (0.60, 1.77)
1.02 (0.56, 1.88)
0.94

0.50

1.04 (0.85, 1.28)
ref
0.83 (0.49, 1.40)
0.80 (0.45, 1.44)
0.45

0.68

1.14 (0.93, 1.40)
ref
1.40 (0.81, 2.42)
1.28 (0.70, 2.36)
0.45

0.19

1.06 (0.86, 1.31)
ref
0.81 (0.48, 1.37)
0.82 (0.44, 1.52)
0.51

0.58

1.26 (1.02, 1.54)
ref
0.89 (0.51, 1.56)
1.32 (0.75, 2.29)
0.29

0.03

1.03 (0.84, 1.26)
ref
1.70 (0.99, 2.91)
1.30 (0.69, 2.47)
0.42

0.80

1.00 (0.81, 1.24)

0.99

0.92
0.94

0.49
0.46

0.23
0.43

0.43
0.53

0.69
0.33

0.05
0.41

Q1:0.002-0.068
ref
ref
Q2:0.070-0.161
1.05 (0.67, 1.63)
0.83
0.81 (0.48, 1.35)
0.42
Q3:0.162-28.17
0.86 (0.50, 1.48)
0.60
0.70 (0.37, 1.32)
0.27
P trend
0.62
0.26
ΣDiBP, μmol/L
Per 1 SD
0.86 (0.68, 1.09)
0.21
0.97 (0.78, 1.21)
0.78
Q1:0.002-0.0083
ref
ref
Q2:0.0084-0.0198
0.96 (0.61, 1.48)
0.84
0.95 (0.57, 1.60)
0.86
Q3:0.020-4.01
0.81 (0.48, 1.38)
0.44
0.86 (0.47, 1.59)
0.64
P trend
0.45
0.64
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MBzP, monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP,
mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP,
di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Modeled using both 1SD standardized phthalates, on the continuous scale, and tertile of phthalates at AV3, among cases and controls, adjusted
for creatinine at AV3, age, region, and hormone therapy use
2Modeled using 1SD standardized phthalates, on the continuous scale, and tertile of phthalates at AV3, among controls only, adjusted for
creatinine at AV3, age, region, and hormone therapy use

72

Table 5.4. Cox regression analyses of the association between phthalate biomarkers at AV3, and adjudicated incident CVD, stratified on HT use, N=1160
Phthalate Biomarker
MBZP, ng/mL
Per 1 SD
Q1:0.21-6.7
Q2:6.8-15.3
Q3:15.4-489
P trend
MCNP, ng/mL
Per 1 SD
Q1:0.2-1.9
Q2:2.0-3.7
Q3:3.8-222
P trend
MCOP, ng/mL
Per 1 SD
Q1:0.2-2.5
Q2:2.6-5.1
Q3:5.2-270
P trend
MCPP, ng/mL
Per 1 SD
Q1:0.14-1.8
Q2:1.9-3.8
Q3:3.9-124
P trend
MEP, ng/mL
Per 1 SD
Q1:0.8-36.5
Q2:36.8-103
Q3:104-15900
P trend
ΣDEHP, μmol/L
Per 1 SD
Q1:0.009-0.124
Q2:0.125-0.271
Q3:0.272-68.47
P trend
ΣDBP, μmol/L
Per 1 SD
Q1:0.002-0.068
Q2:0.070-0.161
Q3:0.162-28.17

Ever use HT, N=7341
HR (95% CI)2

P value

1.11 (0.83, 1.48)
ref
1.41 (0.79, 2.52)
1.48 (0.77, 2.84)
0.24

0.49

1.02 (0.80, 1.30)
ref
1.02 (0.58, 1.80)
1.03 (0.56, 1.91)
0.93

0.88

0.94 (0.72, 1.21)
ref
1.16 (0.65, 2.07)
1.06 (0.57, 1.99)
0.87

0.62

1.09 (0.83, 1.44)
ref
0.90 (0.51, 1.59)
0.92 (0.48, 1.78)
0.80

0.52

1.25 (0.98, 1.58)
ref
1.13 (0.64, 2.00)
1.24 (0.67, 2.27)
0.49

0.07

0.93 (0.72, 1.21)
ref
1.45 (0.84, 2.53)
1.12 (0.56, 2.24)
0.71

0.60

0.95 (0.73, 1.22)
ref
0.81 (0.47, 1.40)
0.61 (0.32, 1.19)

0.67

0.25
0.24

0.95
0.93

0.62
0.85

0.72
0.81

0.67
0.49

0.19
0.75

0.46
0.15
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Never use HT, N=4201
HR (95% CI)2

P value

0.93 (0.64, 1.34)
ref
0.76 (0.35, 1.65)
0.82 (0.34, 1.98)
0.64

0.70

0.89 (0.61, 1.29)
ref
0.53 (0.25, 1.13)
0.66 (0.29, 1.49)
0.26

0.53

1.20 (0.84, 1.72)
ref
1.32 (0.61, 2.85)
1.14 (0.45, 2.86)
0.77

0.32

1.08 (0.75, 1.56)
ref
0.96 (0.43, 2.11)
1.18 (0.49, 2.80)
0.71

0.68

1.36 (0.99, 1.85)
ref
0.45 (0.17, 1.19)
1.74 (0.81, 3.72)
0.11

0.05

1.02 (0.70, 1.48)
ref
1.76 (0.77, 4.01)
1.65 (0.68, 4.01)
0.30

0.92

1.14 (0.76, 1.71)
ref
1.73 (0.79, 3.78)
1.76 (0.67, 4.66)

0.54

0.49
0.65

0.10
0.31

0.48
0.78

0.91
0.71

0.11
0.16

0.18
0.27

0.17
0.25

P Interaction
0.55

0.43

0.96

0.90

0.07

0.81

0.26

P trend
0.15
0.23
ΣDiBP, μmol/L
Per 1 SD
0.77 (0.57, 1.02)
0.07
1.06 (0.73, 1.55)
0.76
Q1:0.002-0.0083
ref
ref
0.58
Q2:0.0084-0.0198
0.92 (0.54, 1.59)
0.78
1.00 (0.47, 2.15)
0.99
Q3:0.020-4.01
0.66 (0.34, 1.28)
0.22
1.19 (0.49, 2.88)
0.70
P trend
0.23
0.71
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MBzP, monobenzyl phthalate; MCNP, mono carboxyisononyl phthalate; MCOP, mono carboxyisooctyl
phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1HT use includes both reported medication use as well as HT intervention assignment, where appropriate, during the 3-year interval.
2Modeled using 1SD standardized phthalates at AV3, on the continuous scale, and tertile of phthalates at AV3, among cases and controls, adjusted for age, creatinine,
and region
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Table 5.5. Cox regression analyses of the association between phthalate biomarkers at AV3, and adjudicated
incident CVD, adjusted for adiposity, N=1,160
Phthalate Biomarker
HR (95% CI)1
P-value
MBZP, ng/mL
1.02 (0.81, 1.29)
0.87
MCNP, ng/mL
0.94 (0.76, 1.16)
0.55
MCOP, ng/mL
0.97 (0.78, 1.21)
0.78
MCPP, ng/mL
1.05 (0.84, 1.31)
0.65
MEP, ng/mL
1.26 (1.04, 1.53)
0.02
ΣDEHP, μmol/L
0.94 (0.76, 1.17)
0.59
ΣDBP, μmol/L
0.98 (0.79, 1.22)
0.88
ΣDiBP, μmol/L
0.86 (0.68, 1.09)
0.22
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MBzP, monobenzyl phthalate; MCNP, mono
carboxyisononyl phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl
phthalate; MEP, monoethyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, diisobutyl phthalate
1Modeled with 1SD standardized phthalates among cases and controls, adjusted for creatinine at AV3, age,
region, hormone therapy use, and BMI at AV3
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Table 5.6. Comparison table of descriptive statistics between BMD participants only versus BMD and AS458 participants
Characteristics
BMD, N=9,763
BMD & AS458, N=1,257
Age; Mean (SD)
63.3 (7.5)
62.5 (6.9)
BMI; Mean (SD)
28.8 (5.9)
28.8 (5.9)
Ethnicity; N (%)
American Indian or Alaskan Native
126 (1.3)
10 (0.8)
Asian or Pacific Islander
30 (0.3)
5 (0.4)
Black or African American
1473 (15.0)
123 (10.3)
Hispanic/Latino
675 (6.9)
59 (4.9)
White (not of Hispanic origin)
7461 (76.1)
993 (82.9)
Other
42 (0.4)
8 (0.7)
HT Arm; N (%)
Not randomized to HT
8152 (83.0)
1032 (82.1)
E-alone intervention
400 (4.1)
44 (3.5)
E-alone control
409 (4.2)
58 (4.6)
E+P intervention
458 (4.7)
69 (5.5)
E+P control
403 (4.1)
54 (4.3)
Abbreviations: BMD, bone mineral density; SD, standard deviation; BMI, body mass index; HT, hormone therapy
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Test p-value
<0.001*
0.94*
<0.001**

0.52**

Table 5.7. Cox regression analyses of the association between phthalate biomarkers, averaged over three years and adjudicated
incident CVD, N=1,160
HR (95% CI)2
N=1160

Phthalate Biomarker1
MBZP, ng/mL
Per 1 SD
Q1:1.82-13.76
Q2:13.77-23.41
Q3:23.42-5767
P trend
MCNP, ng/mL
Per 1 SD
Q1:0.78-3.33
Q2:3.34-5.50
Q3:5.51-227.6
P trend
MCOP, ng/mL
Per 1 SD
Q1:0.1.27-4.53
Q2:4.54-7.49
Q3:7.50-164.03
P trend
MCPP, ng/mL
Per 1 SD
Q1:0.87-3.75
Q2:3.76-5.87
Q3:5.88-75.49
P trend
MEP, ng/mL
Per 1 SD
Q1:9.27-81.83
Q2:81.85-185.01
Q3:185.54-14226.47
P trend
ΣDEHP, μmol/L
Per 1 SD
Q1:0.046-0.228
Q2:0.229-0.369
Q3:0.370-11.31
P trend
ΣDBP, μmol/L
Per 1 SD
Q1:0.175-0.139
Q2:0.140-0.245

P-value

1.0004 (1.000071, 1.00077)
ref
1.05 (0.68, 1.61)
1.02 (0.65, 1.60)
0.95

0.02

0.98 (0.96, 1.01)
ref
1.19 (0.77, 1.83)
0.96 (0.60, 1.52)
0.93

0.25

1.00 (0.98, 1.01)
ref
1.32 (0.86, 2.04)
0.99 (0.62, 1.58)
0.98

0.71

1.02 (1.00, 1.05)
ref
0.87 (0.56, 1.34)
0.89 (0.57, 1.38)
0.58

0.03

1.00013 (0.99, 1.00027)
ref
1.10 (0.69, 1.74)
1.50 (0.97, 2.32)
0.07

0.07

0.78 (0.46, 1.32)
ref
1.49 (0.95, 2.34)
1.44 (0.91, 2.27)
0.13

0.36

1.31 (1.13, 1.52)
ref
1.06 (0.69, 1.63)

<0.001
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0.84
0.92

0.44
0.86

0.21
0.97

0.52
0.60

0.69
0.07

0.08
0.12

0.80

Q3:0.246-11.80
0.98 (0.63, 1.53)
0.94
P trend
0.89
ΣDiBP, μmol/L
Per 1 SD
0.01 (0.00, 14.80)
0.20
Q1:0.0029-0.0149
ref
Q2:0.0150-0.0262
1.09 (0.72, 1.66)
0.68
Q3:0.0263-1.55
0.81 (0.52, 1.27)
0.36
P trend
0.31
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MBzP, monobenzyl phthalate; MCNP, mono carboxyisononyl
phthalate; MCOP, mono carboxyisooctyl phthalate; MCPP, mono-3-carboxypropyl phthalate; MEP, monoethyl phthalate; DEHP,
di(2-ethylhexyl) phthalate; DBP, di-n-butyl phthalate; DiBP, di-isobutyl phthalate
1Phthalate biomarkers used for this analysis were creatinine-standardized and are the average across 2-3 measurements over threeyears.
2Modeled using creatinine-standardized average phthalates, on the continuous scale, and creatinine-standardized average tertile of
phthalates, among cases and controls, adjusted for age, region, and hormone therapy use
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